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ABSTRACT OF DISSERTATION

Multi-stream Longitudinal Data Analysis using Deep Learning
Longitudinal healthcare data encompasses all tasks where patients information are
collected at multiple follow-up times. Analyzing this data is critical in addressing
many real world problems in healthcare such as disease prediction and prevention. In
this thesis, technical challenges in analyzing longitudinal administrative claims data
are addressed and novel deep learning based models are proposed for multi-stream
data analysis and disease prediction tasks. These algorithms and frameworks are
assessed mainly on substance use disorders prediction tasks and specifically designed
to tackled these disorders. Substance use disorder is a public health crisis costing
the US an estimated $740 billion annually in healthcare, lost workplace productivity,
and crime. Early identification and engagement of individuals at risk of developing a
substance use disorder is a critical unmet need in healthcare which can be achieved
by producing automatic artificial intelligence based tools trained using big healthcare
data. In fact, healthcare data can be harnessed together with artificial intelligence and
machine learning to advance our understanding of factors that increase the propensity
for developing different diseases as well as those that aid in the treatment of these
disorders.
Here in, a disease prediction framework is first proposed based on recurrent neural networks. This framework includes three components: 1) data pre-processing,
2) disease prediction using long short term memory models, and 3) hypothesis exploration by varying the models and the inputs. This framework is assessed using
two use cases: substance use disorder prediction and mild cognitive impairment prediction. Experimental results show that this proposed model can efficiently analyze
patients' data and creates efficient disease prediction tools. Second, the limitations
of current deep learning models including long short term memory models in claims
data analysis are detected and addressed, and a novel model based on the transformer

models is proposed. In fact, leveraging the real-world longitudinal claims data, a novel
multi-stream transformer model is proposed for predicting opioid use disorder as an
important case of substance use disorders. This model is designed to simultaneously
analyze multiple types of data streams, such as medications, diagnoses, procedures
and demographics, by attending to segments within and across these data streams.
The proposed model tested on the IBM MarketScan data showed significantly better performance than the traditional models and recently developed deep learning
models.
KEYWORDS: Deep Learning, Longitudinal Data Analysis, Healthcare Data Analysis, Transformer, Recurrent Neural Networks.
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Chapter 1 Introduction

In modern artificial intelligence, longitudinal data encompasses all tasks where a
response is observed on each subject repeatedly over time. What distinguishes longitudinal data from the traditional data sets is that in longitudinal data a temporal
pattern of events is included in the data set in addition to the events' outcomes.
The most common examples of longitudinal data include healthcare data, speech and
natural language data. In healthcare data, patients outcomes and possibly treatments or procedures are collected at multiple follow-up times. Analyzing this longitudinal healthcare data and extracting meaningful knowledge from these growing
data sets is critical in addressing many real world problems in healthcare. However,
analyzing real-world healthcare data is a complicated task with computational challenges including high dimensionality, heterogeneity, temporal dependency, sparsity,
and irregularity1 . In particular, healthcare data is typically collected from multiple sources, and the subsequent data analysis requires simultaneous analysis of the
temporal correlation among multiple streams of different data sources such as medications, diagnoses, and procedures. This study, addresses the challenges in analyzing
longitudinal healthcare data using deep learning models and proposes a novel deep
learning based model to analyze large scale claims data sets. Claims data, also known
as administrative data, are large healthcare data that include person-specific clinical utilization, expenditures and enrollment across inpatient, outpatient, prescription
drug and carve-out services.
1.1

Longitudinal healthcare data analysis using deep learning

Deep learning models have demonstrated great potentials in addressing some of the
challenges in analyzing longitudinal and sequential data and created promising data
analysis tools. Recurrent neural networks (RNNs) such as long short term memory
models (LSTMs)2 are a variety of deep learning model that have shown promising
performance in longitudinal and sequential data analysis and gained popularity in
many natural language processing (NLP) tasks. RNNs have an important characteristic that enables them to deal with the challenges in longitudinal and sequential
data analyses. They are capable of extracting contextual information from past time
steps and pass this information forward, which helps them to efficiently model long
term dependencies in input sequences3 . Nevertheless, the network architecture and
1

design preclude RNNs from processing long streams in a reasonable amount of time4 .
Attention mechanism was introduced in RNNs to increase their capacity in capturing
long range dependencies more efficiently4–6 . Attention-based models bridge the gap
between different states in RNNs using a context vector. Successful applications of
multiple attention layers led to the transformer model7 , which removed recurrence
in RNNs relying entirely on the attention mechanism. These novel models yielded
superior sequence analysis and outperforms state of the art models in almost all of
the natural language processing tasks.
Both RNN and transformer have been successfully used to create longitudinal
healthcare data analysis tools during the past couple of years. Among the deep
learning based healthcare data analysis tools, Doctor AI8 , RETAIN9 , and DeepCare10
modeled multiple data streams including medications, diagnoses, and procedures using recurrent neural network models such as long short term memory models2 . Doctor
AI concatenated multi-hot input vectors to predict subsequent visit events8 . RETAIN
used two separated RNNs to generate attentions at the visit level and the variable
level as well9 . These applications demonstrate that RNNs are promising in longitudinal and sequential healthcare data analysis, since RNNs are capable of extracting
contextual information from past time steps and pass this information forward; this
helps to efficiently model long-term dependencies in patients' data3 . However, as
mentioned above the network architecture and design preclude RNNs from processing
long streams in a reasonable amount of time4 and attention based models including
the transformer were introduced to address this issue. Transformers were applied on
longitudinal electronic health records (EHR)11 to predict patients' outcomes in the future. There are also several models that have been successfully applied on EHR data
without significantly changing the network architecture or loss12–14 . Of course, the
typical transformer's structure can be altered to better fit the special needs of solving
healthcare problems11, 15 . Choi et al. proposed a transformer model for healthcare
data analysis by utilizing the conditional probabilities calculated from the encounter
records to guide the self-attention mechanism in the transformer11 . BEHRT15 was
developed based on BERT16 , a popular transformer model for NLP tasks, for analyzing EHR data. BEHRT considers the patients' existing diagnoses and demographic
data to predict their future diagnoses.
Similar to RNNs, transformers have been modified to model multiple data streams.
Li et al developed a two-stream transformer to analyze both time-over-channel and
channel-over-time features in human activity recognition tasks17 . Two parallel, yet
separate transformers were used to handle two input streams. Another multi-stream
2

transformer has been developed to generate effective self-attentions for speech recognition18 . They parallelized multiple self-attention encoders to process different input
speech frames. Gomez et al. developed a multi-channel transformer for sign language
translation using one self-attention encoder19 . Their model finds the attentions across
three different channels, i.e. hand shapes, mouthing, and upper body pose. A more
recent work20 showed that “transformer is all you need” by using multiple transformer
encoders. The encoded outputs can be concatenated using a joint decoder that enables simultaneous model training. There are also works that analyze multi-stream
data using transformer by simply stacking or parallelizing multiple transformer models21, 22 .
1.2

Motivations

Longitudinal healthcare data analysis is critical in addressing many real world problems in healthcare including substance use disorder (SUD). Early identification and
engagement of individuals at risk of developing a SUD is a critical unmet need and
public health emergency23, 24 . The 2018 National Survey of Drug Use and Health
reports that over 20 million people aged 12 and over have a SUD, with over 2 million
reporting an opioid use disorder (OUD). Individuals with OUD often do not seek
treatment or have internalized stigma about OUD that limits identification through
traditional means, such as screening and clinical interview25 . Significant disparities
limit access to treatment for OUD resulting in less than 20% of all individuals with
OUD receiving any form of treatment in the past year26 . Since individuals are reluctant to seek treatment, one solution is to identify patients otherwise engaged in the
healthcare system where a majority of ambulatory care is provided, primary care27 .
While there are currently tools developed to predict aberrant behavior when prescribing opioids28 or to predict OUD from a general primary care population29 , there
are only a few clinical tools, such as the Opioid Risk Tool30 , developed for assessing the risk of OUD. Typical clinician workflow does not allow for comprehensive
OUD screening, but available administrative and clinical data have the potential to
help clinicians identify and screen higher risk patients providing an opportunity for
primary care professionals to play a greater role in increasing OUD and SUD detection, treatment, and prevention. Healthcare data including claims data is a growing
source of information that can be harnessed together with deep learning and machine learning to advance our understanding of factors that increase the propensity
for developing OUDs and SUDs as well as those that aid in the treatment of the

3

disorders31, 32 .
Although the recently developed deep learning based models such as transformer
models have shown promising performance, the potential of applying transformers on
claim data analysis has not yet been fully explored. One of the major limitations of
the current deep learning models is the lack of capacity to model multiple data streams
within the self-attention layer. The transformer was originally designed to process one
data stream, which is mostly an order of words in a NLP task, at a time. The modified
transformers either can only handle multiple streams at intra-stream level or they are
not suitable to solve SUD and OUD prediction problems targeted in this thesis.
Here, OUD prediction is complex data analysis task that includes not only finding
long term effects of prescription opioids such as morphine and fentanyl, history of
diagnoses such as mood disorders, but also the hidden associations between patient’s
prescriptions and diagnoses, since these input streams are highly correlated with each
other. Identifying the relationships within and between input streams may reveal
hidden patterns leading to an increased classification ability and interpretability for
OUDs. Moreover, the medication application patterns and the interactions between
medications across different visits as well as the patient's diagnoses and procedures
patterns thorough his/her medical history may carry important information that
should be extracted in order to develop precise and sensitive OUD identification and
prediction tools.
This thesis, first proposes a framework to efficiently use RNNs including long short
term memory models and the transformer in analyzing claims data sets and develop
disease prediction tools. Then, the limitations of using transformers in healthcare
data analysis are addressed and a novel transformer model to analyze longitudinal
healthcare data collected from multiple sources is proposed. Leveraging the realworld longitudinal claims data, this work proposes a novel multi-stream transformer
for longitudinal claims data analysis and disease prediction. The proposed model
is designed to simultaneously analyze multiple types of data streams, such as medications, diagnoses, procedures and demographics, by attending to segments within
and across these data streams. Multiple real-world problems in healthcare including
substance use disorder, opioid use disorder and mild cognitive impairment are used
to assess the proposed LSTM and transformer based models.

4

1.3

Contributions

The purpose of this thesis is to address challenges in analyzing longitudinal claims
data using deep learning and develop novel models for disease predictions. To this
end, multiple deep learning based models are proposed. First, this work addresses the
technical challenges in analyzing temporal claims data and presents a new framework
to perform disease prediction tasks using recurrent neural networks. This framework
has three components: 1) data pre-processing, 2) disease prediction using RNNs,
and 3) hypothesis exploration by varying the model and inputs. Second, this thesis
extends and applies the transformer to real-world longitudinal claims data analysis
tasks. Transformer traditionally processes one stream of inputs which is mostly an
order of words in a NLP task. However, claims data analysis tasks require the model
to analyze multiple input streams at the same time and extract the associations
within and between all input sequences. In healthcare, the data is normally from
multiple resources and each patient's data include multiple streams such as medications, diagnoses, procedures and demographics. Further, the attention mechanism in
transformer can be utilized to make the deep learning models more transparent in
applications such as healthcare data analysis where finding the association between
events plays an important role in decision making. This work addresses these challenges and proposes a novel transformer to efficiently process the claims data and
produce disease prediction models. The contributions of this thesis are:
• Producing an open source tool to convert large scale administrative claims data
to a temporal format appropriate for training deep learning models.
• Proposing and developing a novel multi-stream transformer model for disease
prediction using large administrative claims data. This proposed model is designed to simultaneously analyze multiple types of data streams including medications, diagnoses, procedures and demographics by attending to segments
within and across these input data streams.
• Training multiple machine learning and deep learning models using data from
more than 390K patients over 10 years to predict the onset of opioid use disorder.
• Creating a framework to predict the onset of substance use disorder among
adolescents with attention deficiency hyperactivity disorder using long short
term memory models.
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• Proposing a long short term memory based framework to analyze the potential
for patient clustering using routinely-collected EHRs and predict the progression
from cognitively unimpaired to mild cognitive impairment.
• Producing risk identification and data visualization tools for longitudinal claims
data.
1.4

Overview of Thesis

This thesis is organized into five chapters: fundamentals are presented in chapter 2,
chapter 3 introduces the recurrent neural network based models developed in this
thesis to perform disease prediction tasks. In this chapter, substance use disorder
and mild cognitive impairment are used as use case diseases to predict their onset
using the developed RNN based models. Chapter 4 describes the proposed multistream transformer models. This chapter is focused on predicting opioid use disorder
using the proposed multi-stream transformer. Chapter 5 provides detailed discussions
on the methods and results as well as the limitations of the current work and some
suggestions to improve upon this work and guidelines for future works.

Copyright© Sajjad Fouladvand, 2021.
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Chapter 2 Technical Background

In this chapter, material and methods that are used in building the proposed models
are described. Recurrent neural networks are presented in section 2.4. This chapter
also covers attention mechanisms and backgrounds on the transformer model in sections 2.6 and 2.7, respectively. Classical machine learning models including random
forest, visualization and clustering methods as well as the data set used in this work
are also covered in the current chapter.
2.1

IBM MarketScan Data Set

Here in, the large-scale administrative records in the IBM Health MarketScan Commercial Claims database (formerly known as Truven) for the years 2009 to 2020
were used to train and test baseline and proposed algorithms. Data include personspecific clinical utilization, expenditures and enrollment across inpatient, outpatient,
prescription drug and carve-out services. This database contains about 30 million
enrollees annually across the US, and these enrollees are nationally representative of
the US population with respect to sex (50% female), regional distribution, and age.
Though the population is disproportionately privately insured and middle class,
the very large sample supports well-powered subgroup analysis. The IBM MarketScan
databases link paid claims and encounter data to detailed enrollee information across
sites, types of providers, and over time. Historically, more than 20 billion service
records are available each year. These data represent the medical experience of insured
employees and their dependents for active employees, early retirees and Medicareeligible retirees with employer-provided Medicare Supplemental plans. To provide
an example of the sample size available when selecting specific subgroups, Figure
2.1 shows the 2004 data cohort for members with attention deficiency hyperactivity
disorder (ADHD) and prescribed stimulants, along with their yearly follow-up. In
2004 there were 283,421 members with ADHD, with the sample size reduced each
successive year due to follow-up. Each successive year would have a similar cohort
and similar follow-up, with the combined sample population yielding over 500,000
members that will produce well powered subgroup analysis. Further, Table 2.1 provides some basic statistics on the amount of data available from IBM MarketScan
data that is available in this work.
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Figure 2.1: IBM MarketScan Health Analytics sample size for 2014 for each state.
2.2

Classical Machine Learning Models

Here, random forest and other classical machine learning models used as baselines in
this thesis are introduced.
2.2.1

Random Forest

Random forest33 are ensemble models that can be used to solve prediction tasks such
as disease prediction. This model operates by constructing a multitude of decision
trees at training time and has been used extensively to solve predictions tasks in
healthcare data analysis or served as a baseline when deep learning models are used
to create predictive modelings. The goal is to create a predictive model to predict
Y ∈ R given a training data set Sn = (X1 , Y1 ), (X2 , Y2 ), ..., (Xn , Yn ) of independent
random variables distributed as the independent prototype pair (X, Y )34 . For each
tree Tj in a forest including M trees, the predicted value for the input sample x
is denoted by mn (x; Θj , Dn ), where Θ1 , ..., ΘM are independent random variables,
distributed the same as a generic random variable Θ.
mn (x; Θj , Sn ) =

X
i∈S0n (Θj )

1xi ∈ An (x; Θj , Sn )Yi
Nn (x; Θj , Sn )

(2.1)

Where S0 is a subset of data and An (x; Θj , Sn ) is the leaf containing x and
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Table 2.1: Statistics of the subset of IBM MarketScan data available in this work.
The data includes prescriptions, diagnoses, procedures and demographics information
for a large and nationally representative sample of the US population.
Measurement

Number
of
records/patients
or date

Demographics
Female patients

84,114,853

Minimum birth date

1889

Maximum birth date

2020

Data availibility
Earliest service/fill date

01/01/2009

Latest service/fill date

06/30/2020

Number of records
Number of prescription records

3,865,125,856

Number of diagnose records

8,171,102,764

Number of procedure records

10,917,467,123

Number of patients
Unique patients in demographics table

164,148,434

Unique patients in prescriptions table

95,841,261

Unique patients in diagnoses table

133,958,766

Unique patients in procedures table

133,370,031

Nn (x; Θj , Sn ) is all the points that are included in An (x; Θj , Sn ). The random forest
algorithm then combine all the trees to create the final random forest:
M
1 X
mn (x; Θj , Sn )
mM , n(x, Θ1 , Θ2 , ..., ΘM , Sn ) =
M j=1

2.3

(2.2)

Clustering and Visualization

In this work, multiple methods have been use to cluster and visualize the data sets
at different stages of the projects. This section provides a background on the main
clustering and visualization methods used thorough this thesis.

9

2.3.1

K-Means clustering

The k-means algorithm35 is an unsupervised learning algorithms that has been utilized
in many problem domains. In k-means clustering algorithm, n input patterns are
divided into k clusters in which each pattern belongs to the cluster with the nearest
mean (cluster center). The k-means algorithm places the cluster centers as distant
as possible from each other. This method can be summarized in the following steps:
• Initialize K points within the feature space of the training samples randomly,
as initial clusters' centers.
• Assign each training sample x to the cluster with minimum euclidean distance
between the cluster center and x (Equation 2.3).
• When all training samples have been assigned, recalculate new means for each
cluster and consider these mean values as new centers for the new clusters.
• Repeat Steps 2 and 3 until the centers no longer move. This algorithm minimizes
the error function in Equation 2.4.
v
u n
uX
d(x, u) = t (xi − ui )2

(2.3)

i=1
k X
n
X
(j)
j=
kxi − cj k2

(2.4)

j=1 i=1

In Equation 2.4, k and n are the number of clusters and the number of training
P P
(j)
samples, respectively. Also, kj=1 ni=1 kxi − cj k2 indicates the Euclidean distance
(j)

from the sample xi to the cluster center cj . Then, a new sample is characterized by:
f (x) = minj (x − cj )2
2.3.2

(2.5)

t-Distributed Stochastic Neighbor Embedding

t-Distributed Stochastic Neighbor Embedding (t-SNE)36 is an unsupervised, nonlinear technique primarily used for data exploration and visualizing high-dimensional
data. The technique is a variation of stochastic neighbor embedding37 that is much
easier to optimize, and produces significantly better visualizations by reducing the
tendency to crowd points together in the center of the map. The t-SNE algorithm
calculates a similarity measure between pairs of instances in the high dimensional
10

Figure 2.2: Unrolled structure of RNNs. The circles present hidden layers, it , ot
and ht are respectively input, output and hidden state at time step t.
space and in the low dimensional space. This algorithm attempts to optimize visualization in a low dimensional space by matching the distributions using KL divergence.
These pairwise similarities in higher and lower dimensional spaces are modeled using
conditional probabilities38 :
pj|i

exp(−kxi − xj k2 /2σi2 )
2
2
k6=i exp(−kxi − xk k /2σi )

=P

(2.6)

Where pj|i is the conditional probability that a point j is a neighbor of point
i in the higher dimensional space and it models the target distribution of pairwise
similarities in the lower dimensional embedding space using a Student's t-distribution
around each data point to overcome the over- crowding problem in the Gaussian
distribution:
(1 + kyi − yj k2 )−1
2 −1
k6=l (1 + kyk − yl k )

qij = P

(2.7)

t-SNE then minimizes the KL divergence between the distributions, which conserves the local structure of data points across the higher and lower dimensional
spaces.
2.4

Recurrent Neural Networks

A recurrent neural network (RNN) is a class of artificial neural networks where connections between nodes form a directed graph along a temporal sequence. This allows
it to exhibit temporal dynamic behavior. Unlike feed forward neural networks, RNNs
can use their internal state (memory) to process sequences of inputs. This makes
them powerful models in processing longitudinal data. Figure 2.2 shows a full RNN
structure, where the circles represent the network layers and the solid lines represent
the weighted connections3 .
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Figure 2.3: A LSTM memory cell. Each LSTM unit includes the input gate, the
output gate and the forget gate.
RNN computes a set of hidden states h = (h1 , h2 , ..., hT ) as well as output vectors
y = (y1 , y2 , ..., yT ) for a given input sequence x = (x1 , x2 , ..., xT ) when T is the number
of time steps. RNN iterates over the input sequence and computes the hidden states
and outputs using the following equations39 :
ht = F (Wxh xt + Whh ht−1 + bh )

(2.8)

yt = Why ht + by

(2.9)

Where the W is a trainable weight matrix, the b is a trainable bias vector and
F is the hidden layer function. In the following section, Long Short Term Memory
model which is one of the most popular RNN models have been described.
2.5

Long Short Term Memory Model

The long short term memory model is one of the most powerful and popular RNN
models. The LSTM has already been deployed successfully in analyzing temporal
data in many biomedical applications40–43 . In particular, the LSTM alleviates the
vanishing gradient problems44 and bridges time intervals in a sequence. In a LSTM
model, nodes are replaced with a unit called memory cell as shown in Figure 2.345 .
A memory cell includes the input gate, output gate, and forget gate. The input
gate decides how to update the cell state using the new input and the output gate
determines how to filter the output. The forget gate decides which information the
LSTM is going to forget; it considers both it and ht and then, utilizing a sigmoid
function, it generates a matrix with elements between 0 and 1. The previous cell
state will be element-wisely multiplied by the numbers generated by the forget gate
to determine how much information the LSTM unit wants to keep.
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The most common LSTM architecture is given by the following equations3 :
it = σ(Wxi xt + Whi ht−1 + Wci ct−1 + bi )

(2.10)

ft = σ(Wxf xt + Whf ht−1 + Wcf ct−1 + bf )

(2.11)

ct = ft ct−1 + it tanh(Wxc xt + Whc ht−1 + bc )

(2.12)

ot = σ(Wxo xt + Who ht−1 + Wco ct + bo )

(2.13)

ht = ot tanh(ct )

(2.14)

Although LSTMs could partially solve vanishing gradients problems, it still suffers
from the complexity of sequential path from older past cells to the current one. Moreover, LSTM's sequential nature precludes parallelization within training examples,
which causes low computational efficiency in training using longer sequence lengths.
This limitation motivated researchers to improve efficacy of RNNs using methods
such as factorization tricks and attention mechanisms.
2.6

Attention Mechanism

Traditional sequence-to-sequence modeling include encoder and decoder where encoder map the input sequence to a fixed length vector and the decoder consumes
this vector to generate the target sequence. However, it has been shown that the
use of a fixed-length vector and simply feeding that into a decoder precludes improving the performance of this basic encoder–decoder architecture. Attention mechanism5, 6 boosted the RNNs performances in sequence modeling. Attention-based
models bridge the gap between hidden states in encoder and the decoder using a
context vector. In fact, the context vector computes the probability distribution of
input sequence values at different time steps for each output that decoder generate
each at each step.
The idea of a attentional model is to consider all the hidden states when deriving
the context vector ct . In this model type, a variable-length alignment vector at , whose
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size equals the number of time steps on the source side, is derived by comparing the
current target hidden state ht with each source hidden state hs :
αt (s) = align(ht , hs ) = P

exp(score(ht , hs ))
s0 (exp(score(ht , hs0 )))

(2.15)

The score function is referred as a content-based function for which three different
alternatives are considered in5 :



h >h
dot

 t s
score(ht , hs ) = ht > Wa hs
general



υ > tanh(W [h ; h ] concat
a t
s
a

(2.16)

Attention-based models showed promising performance in many NLP tasks and
they later led to the transformers which outperformed all previous models in many
language modeling problems.
2.7

Transformer: Attention is All You Need

The transformer was first proposed7 based solely on attentions. Sequential nature of
recurrent neural networks is a barrier to parallelization during training using long sequences. Attention mechanisms have been introduced to be used in conjunction with
RNNs to model longer dependencies in sequences more efficiency. Transformers are
model architectures that removed recurrence and instead relied entirely on an attention mechanism to draw global dependencies between input and output.Transformers
were superior in quality while being more parallelizable and requiring significantly
less time to train. They led to powerful neural machine translation models such as
GPT46 , BERT16 , XLNet47 and ALBERT48 .
Transformers, as neural sequence transduction models49 , consists of two main components: encoder and decoder. The encoder maps an input sequence x = (x1 , ..., xn )
to a new representation z = (z1 , ..., zn ). The decoder part auto-regressively generate the output y = (y1 , ..., ym ) using z and previous outputs at each step. Figure
2.4 shows the overall architecture of the tsransformer. Both encoder and decoder
layers include similar components: Multi-Head Attention, layer normalization, and
position-wise fully connected feed-forward network. Multi-Head attention plays the
most critical role within encoder and decoder layers.
The input to the attention function in transformer is set of queries, keys and
values. The function calculates the weighted sum of input values where the weight
14

Figure 2.4: The Transformer - model architecture.
assigned to each value is computed using a soft-max of normalized dot product of
query and key vectors. Mathematically speaking, the output vectors are computed
as:

QK T
Attention(Q, K, V ) = sof tmax( √ )V
dk

(2.17)

Where, dk is the dimension of the model and Q, K, and V are query, key and
value vectors, respectively.
The transformer use another mechanism called multi-headed attention to first
enables the model to focus on different positions of the input and second, provides the
attention layer multiple representation subspaces. Multi-headed attention is simply
running the attention procedure described above in parallel and concatenating the
outputs:
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M ultiHead(Q, K, V ) = Concat(head1 , ..., heanh )W O
where headi = Attention(QWiQ , KWiK , V WiV ) (2.18)
Where the projections are parameter matrices WiQ ∈ Rdmodel ×dk , WiK ∈ Rdmodel ×dk ,
WiV ∈ Rdmodel ×dv and W O ∈ Rhdv ×dmodel .
2.8

Conclusion

This section provided detailed information on material and methods including IBM
MarketScan data, classical machine learning models, recurrent neural networks, long
short term memory model, and transformer models which are all parts of material and
methods used in this thesis. In the following chapters, the above mention methods
will be used to introduce the novel methods and frameworks proposed in this thesis.
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Chapter 3 Longitudinal Data Analysis using LSTM

This chapter compares the performance of traditional machine learning and statistical
methods to a proposed recurrent neural networks based model on two disease prediction tasks: SUD prediction in claims data and MCI prediction in EHR data. Bayesian
statistics, Support Vector Machines, Random Forests, and Bayesian Statistics were
used as traditional models to be compared with the deep learning models.
3.1

LSTM prediction of SUD

Here in, a deep learning based framework is proposed to capture the temporal patterns
in patients information and predict the onset of substance use disorder. One of the
potential risk factors for the development of SUD is an attention deficit hyperactivity
disorder (ADHD) diagnosis. ADHD is one of the most prevalent neuropsychiatric
disorders, with 6-10% of children (aged 2-17) received a diagnosis50 . Given that 62%
of individuals diagnosed with ADHD receive medication therapies51 , it is critical to
systematically assess the long-term association of ADHD medication on subsequent
risk of SUD.
The Spontaneously Hypertensive Rat (SHR) model of ADHD has been extensively used to assess the impact of exposure to specific ADHD medications52–58 . Using the SHR model, it has recently been reported that never medicated rats with
an ADHD phenotype self-administered more cocaine than those without an ADHD
phenotype. Moreover, the ADHD medication introduced during adolescence was an
important factor associated with a further increase in cocaine self-administration in
young adulthood52–58 . These preclinical findings suggest that medication type and
age of medication initiation are critical factors in the relationship between ADHD
pharmacotherapy and subsequent SUDs.
In this study, the technical challenges in analyzing temporal medication data were
addressed and present a new framework to predict the long-term impact of ADHD
medication initiated during adolescence. This framework has three components: 1)
data pre-processing, 2) SUD prediction using RNNs, and 3) hypothesis exploration
by varying RNN and inputs. Experimental results show that temporal medication
features of ADHD medication initiation during adolescence, rather than stationary
features (e.g., medication type, age, sex), are the most important factors on the health
consequences related to SUD.
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Figure 3.1: Cohort extraction and data pre-procesing schema.
3.1.1

Data Pre-processing

All the ADHD-related records from IBM MarketScan between Jan 2009 and Dec
2015 were extracted. Figure 3.1 shows the flowchart of cohort selection and data
pre-processing. All the 254,996 individuals who had an International Classification of
Disease (ICD-9) diagnosis of ADHD (ICD-9 code 314.X) were selected; among them
136,933 are children (6-12 years) and 118,063 are adolescents (13-20 years) onset
exposure to ADHD medication. For each of the enrollees with an ADHD diagnosis,
all the ADHD medication records between Jan 2009 and Dec 2015 were extracted.
In total, 11,778,912 records from IBM MarketScan were extracted.
The original format of the prescription and professional service encounter claims
in IBM MarketScan is a table where each row is a visit and columns are enrollee ID,
date of visit, and prescription. If an enrollee has multiple visits, each visit will occupy
a row in the table. To facilitate further study of the temporal patterns in the data, the
IBM MarketScan format was converted into an enrollee-time matrix X(P, T ), where
P is the complete set of ADHD enrollees and T is the set of time points between
Jan 2009 and Dec 2015 (by month), each cell xij records the medications an enrollee
pi took at time tj . Figure 3.2 shows the cohort definition and describes the process
mentioned above. Here twelve ADHD medications were considered and categorized
into four medication groups, i.e. amphetamines, methylphenidate, modafinil, and
others, based on the first eight digits of the generic product indicator (see Table 3.2
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Figure 3.2: Cohort definition: All ADHD-related records from IBM MarketScan
between January 2009 to December 2015 have been extracted. The SUD-cohort
includes ADHD individuals who has been diagnosed as having a SUD for the first
time after he/she has received a prescription for an ADHD medication for at least five
months. The SUD-control cohort includes ADHD individuals without any diagnosis
of SUD during the follow up period.
for details). Given the monthly subscription records in IBM MarketScan, the finest
temporal resolution of T is by month.
Enrollee's demographic information including age and sex, were directly plugged
into the longitudinal ADHD medication records, and then trained the LSTM. Specifically, for enrollee pi at time step tj , the age of pi at tj were converted into to a bit
vector, which was then concatenated the vector with the ADHD medication record
in cell x(i, j). Similarly, an additional bit was used to incorporate the sex information. This new format allows to model both temporal and stationary features
simultaneously.
If an enrollee in P has been diagnosed as having a SUD for the first time after
he/she has received a prescription for an ADHD medication for at least five months
were determined. If this condition is met, the enrollee is labeled as ADHD-SUD
positive (label yi = 1 for enrollee pi ) and all the ADHD medications after the first
SUD diagnosis will be removed from X(P, T ); otherwise the enrollee is labeled as
ADHD-SUD negative (label yi = 0 for enrollee pi ). The extracted IBM MarketScan
data include detailed enrollee-level information over time, ready for assessing the
long-term impact of ADHD medications. Figure 3.3 shows a simplified example of
the longitudinal medical record data that have been created for an enrollee, and
Figure 3.4 visualizes the entire medical record data. Each row in Figure 3.4 has a
similar format to what is described in Figure 3.3; each pixel in each row is related to
a time stamp (one month) and its color shows the ADHD medication that an enrollee
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Figure 3.3: A simplified example of the longitudinal medical record data. Each entry
corresponds to a time step (a specific month) and shows the ADHD medications that
enrollee was prescribed. If the enrollee did not use any medication during a specific
month, the entry will be 0.
was prescribed.
Further, to determine type and pattern of medication exposure during adolescence,
male and female IBM MarketScan enrollees who initiated any ADHD medication between 13-20 years old were selected (Table 3.1). Medication utilization was based
on the first medication prescribed (i.e., initiated medication) and the medication prescribed in ≥ 50% of medicated months (i.e., primary medication). Amphetamine was
the first prescribed medication for over half, and methylphenidate was the first prescribed medication in over a third of male and female adolescents. Initial medication
was the primary medication 90% of the time. No sex differences were found, with
the exception of a greater lag time from ADHD diagnosis to first ADHD medication
in males compared to females (1.6 and 0.3 months, respectively; not shown). Number
and length of gaps in medication use averaged 1.5 breaks for a total of 3 months over
the course of 12 months. Among enrollees who switched medications, an average of
1.6 medication switches occurred (Figure 3.5, heat map for visualization of 16-year
old sample). When amphetamine was both the initial and primary medication, an
SUD diagnosis was found in 10.2% of enrollees. In contrast, when methylphenidate
was both the initial and primary medication, an SUD diagnosis was found in 8.2%
of enrollees. Although preliminary, this suggests that amphetamine increases risk
for SUD. It is important to consider other factors, such as role of ADHD severity in
medication prescribing, as it may be disease severity, rather than specific medication
that increases SUD risk.
On average, every enrollee has 74.4 visits and among them, the average number
of visits for ADHD-SUD positive enrollee is 61.2. Regarding the type of ADHD
medications that enrollees used, 39.3% of enrollees used amphetamine as their initial
ADHD medication while 52.9% initiated with methylphenidate. Only a small portion
(almost one percent) of enrollees were prescribed both as their first prescriptions. A
medication is called the primary medication for an enrollee if the prescriptions for that
medication occupy more than 80% of that enrollees ADHD medication prescriptions.
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Table 3.1: Utilization of ADHD Medications initiated during adolescence (13-20
years) by sex. Amphetamine was the most common initiated and primary medication
prescribed during adolescence, followed by methylphenidate. Primary medication
designation is defined as the medication that was prescribed on ≥ 50% of medicated
months. *On average, the primary medication was prescribed to enrollees on ≥ 95%
of medicated months.
Medication History

Males
921)

(n=137,

Females
(n=88,834)

-

n(%)

n (%)

Amphetamine

73,262 (53.1%)

51,134 (57.6%)

Methylphenidate

51,751 (37.5%)

30, 592 (34.4%)

Other

12, 037 (8.7%)

6, 702 (7.5%)

None

871 (0.6 %)

406 (0.5%)

Amphetamine

75, 461 (54.7 %)

53, 309 (60.0 %)

Methylphenidate

48, 646 (32.3 %)

27, 733 (31.2%)

Other

10, 968 (8.0%)

5, 732 (6.5%)

None

2, 846 (2.1 %)

2.060 (2.3%)

Initiated Medication

Primary Medication

Given the definition, 33.2% of enrollees are prescribed amphetamine as the primary
ADHD medication and 40.2% of enrollees are prescribed methylphenidate as the
primary ADHD medication. According to the above basic statistics, there is no
significant bias in the data towards SUD. More sophisticated methods are required
to extract knowledge from the IBM MarketScan data.
Note, although adolescent ADHD medication initiators in the IBM MarketScan
data are represented less than child-initiators, for those who are ADHD-SUD positive, data from adolescent enrollees are abundant, whereas data from children are
insufficient for this analysis (see Figure 3.6). Therefore, although a limited subset of
IBM MarketScan data is used in this study, it is still appropriate to study the impact
of the initiation of ADHD medication in adolescent enrollees.
Furthermore, two problems in the IBM MarketScan data were addressed first,
i.e. data sparsity and label imbalance problems. First, data sparsity was reduced.
This is an important problem since in the enrollee medication record matrix X(P, T ),
96.6% of medication records are simply empty (noted as zero). To address this, all
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Figure 3.4: Visualization of the longitudinal data. Left figure describes SUD negative enrollees and right figure describes SUD positive enrollees. Enrollees are sorted
based on their ages and in the right figure (SUD positives) they are also sorted based
on the SUD diagnosis dates. Note, black dots highlights the time stamp when the
ADHD enrollee is diagnosed with SUD.

Table 3.2: Generic product indicator of ADHD medications.
GPI Code

Medication

Relevant Grouping

61100010
61100020
61100025
61100030
61109902

Amphetamine
Dextroamphetamine
Lisdexamfetamine
Methamphetamine
Amphetamine Mixtures-Two Ingredient

61400010
61400024

Armodafinil
Modafinil

61400016
61400020

Dexmethylphenidate
Methylphenidate

61353020
61353030
61354015

Clonidine
Guanfacine
Atomoxetine

Amphetamines

Modafinil
Methylphenidate
Other
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Figure 3.5: Heat map of IBM MarketScan members who initiated ADHD medication at 16 years of age to demonstrate sex differences in the utilization of ADHD
medication across time (See Fig. 3-A, green box). Medication utilization in a sample
of 1,000 male (left) and 1,000 female (right) enrollees with an ADHD diagnosis who
initiated ADHD medication at 16 years. Each row represents one enrollee and colors represent the absence or presence of medication (methylphenidate, amphetamine,
other) exposure on a monthly basis. Heat maps illustrate variability in medication
utilization characteristics, including change in number and length of gaps*, medication types**, discontinuation of medication*** and continuous medication****.
the empty records were removed before the first ADHD medication record or after
the last ADHD medication record. In addition, empty sequences, sequences in which
the enrollee used ADHD medication for less than five months, and enrollees who
started using ADHD medication less than five months prior to being diagnosed with
SUD were all removed to further reduce noise and remove outliers. In the literature,
three, six and twelve months break are commonly used as a baseline cut of value to
determine whether the medicine initialization is authentic59, 60 .
However, long ADHD breaks usually happen during the summer break which is
approximately 2.5 to 3 months in the United States. It is clear that three-month break
is too short and six or twelve-month break is too long. Alternatively, the five-month
break was used based on our previous experiences with Spontaneously Hypertensive
Rat (SHR) model of ADHD52–58 . Using the five-month break also slightly enlarged
the data set size from 10,836 to 11,462 (almost 6% increase) compared with using
the six-month breaks. Second, the label imbalance problem were addressed. The
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Figure 3.6: Visualization of data availability in the IBM MarketScan data. Red
indicates abundant medical records, black indicates insufficient medical records, and
green means NA. Only the ADHD enrollees who develop SUD are included. Figure
shows that in the IBM MarketScan data, data from adolescent ADHD enrollees are
abundant, while data from children with ADHD are insufficient for analysis.
IBM MarketScan data include in total 118,063 enrollees with adolescent initiation of
ADHD medication, 9,376 of them are ADHD-SUD positive and 108,687 of them are
ADHD-SUD negative.
The positive and the negative datasets are highly unbalanced and this can significantly affect training and optimization of any type of neural networks61, 62 . In
this study, a data level approach called focused under-sampling63 were adopted to
deal with the class imbalance problem. Zero-padding were first applied to the input
sequences so that the sequence lengths are the same, which makes it feasible for sequence comparison. Note, LSTM model handles variable length sequences and this
zero padding strategy is only used during the pre-processing phase. Then, the cosine similarity64 were applied to compare these sequences. The cosine similarity were
defined between two sequences u and v as (assume each timestamp is i.i.d):
cosine(u, v) = 1 −

(u.v)
||u||2 ||v||2

(3.1)

For every SUD-positive sample, one (or five) of the most similar SUD-negative
samples from the ADHD-SUD negative enrollee pool were selected using cosine simi-
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larity (Equation 3.1), thus a balanced (or a slightly unbalanced) dataset was generated
to train the models.
3.1.2

Experimental Settings

All the LSTM models were deployed on the TensorFlow platform65 and were trained
using eight GeForce GTX 1080 GPUs. Batch size, learning rate, number of hidden
neurons and number of epochs were set to be 256, 0.09, 75 and 100, respectively. Support Vector Machine (SVM)66 , Random Forest (RF) models67 , and Bayesian Statistics
as well as two dummy models which label all validation samples as either negatives
or positives were compared with the LSTM models.
For systematic performance testing, each time 90 percent of the data were randomly selected as training data and the other 10 percent as testing data and this
process was repeated 20 times. Averaged performance on the unseen folds was reported as the final result. Parameters of SVM and RF were tuned using a 20-Fold
cross-validation and the averages of the best validation performance were reported in
Table 3.4. Note that the performance of the baselines were even poorer than the validation performance. Accuracy, precision, recall, specificity and F1-score were used
to evaluate and compare different models68 . In all models, ADHD individuals with
SUD were considered as the positive samples and ADHD individuals without SUD
as the negative samples.
3.1.3

Bayesian statistics

IBM MarketScan is a complex national biomedical dataset. To better understand the
data, Bayesian statistics were used to explore this data. Specifically, the conditional
probabilities of SUD given different types of ADHD medications were computed and
compared.
First, based on data availability, the IBM MarketScan data was stratified into six
subsets based on ADHD medication initiation age (13-18 years). For every subset,
the probability of the SUD diagnosis for enrollees with ADHD were calculated for
two types of initial ADHD medications, i.e. methylphenidate, P (SU D | Mme ) and
amphetamine, P (SU D | Mam ). These estimated probabilities (prevalence rates) can
be included in a ratio to describe the relative probability (prevalence) of SUD for
enrollees initiating on these medications. Table 3.3 shows an observed age-effect
where those in the oldest age strata who initiated on amphetamine have elevated
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Table 3.3: Estimated age-stratified probabilities. P (Mam ) and P (Mme ) are the
probabilities of receiving amphetamine or methylphenidate as the first ADHD medication, respectively; and P (Mme | SU D) and P (Mam | SU D) are the probabilities of
initiating on methylphenidate or amphetamine as the first ADHD medication within
the population of enrollees with SUD.
Initiation
age

P (Mme | SU D)

P (Mam | SU D)

P (Mme ) P (Mam )

P (SU D|Mme )
P (SU D|Mam )

13
14
15
16
17
18

0.58
0.52
0.52
0.47
0.42
0.37

0.41
0.48
0.48
0.53
0.58
0.63

0.59
0.56
0.54
0.51
0.47
0.43

0.99
0.93
0.97
0.93
0.91
0.90

0.41
0.44
0.46
0.49
0.53
0.57

probabilities (prevalence) of SUD, relative to those who initiated on methylphenidate
(last column provides relative probability ratios or prevalence rate ratios).
However, these estimates are limited by only describing medication at initiation.
This summary measure does not encompass a more comprehensive picture of medication utilization, and the over-simplification could miss important relationships between age at initiation, medication patterns, and subsequent SUDs in enrollees with
ADHD.
3.1.4

Deep learning versus traditional methods

Here in, the SUD prediction performances of LSTMs, SVM, RF, and two dummy
models were compared. Performance of the LSTM models, dummy models, and traditional classification models (SVM and RF) are provided in Table 3.4. In Table 3.4,
the models “All-Negatives”, “All-Positives”, “RF”, “SVM” and “LSTM” are all trained
and tested on the balanced dataset. In Table 3.4, regarding the balanced IBM MarketScan data, the LSTM model has the highest accuracy (0.84), precision (0.96),
specificity (0.97) and F1-Score (0.82). The results indicate that LSTM captures important factors in the IBM MarketScan data providing increased power to predict the
development of SUD, while SVM and RF miss such factors.
In addition, model performances were tested on two unbalanced IBM MarketScan
datasets, i.e. Unblnc1 (positive-negative ratio being 0.20) and Unblnc2 (positivenegative ratio being 0.08 when the complete IBM MarketScan data were used). Table 3.4 shows the model performances on Unblnc1 and Unblnc2; X-Unblnc1 repre-
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Table 3.4: Performance of SUD prediction using traditional classification models
and the LSTM model.
Model

Size of Accuracy
Data

Precision

Recall

Specificity F1Score

AllNegatives

11,624

0.50

0.00

0.00

1.00

0.00

AllPositives

11,624

0.50

0.50

1.00

0.00

0.67

RF

11,624

SVM

11,624

LSTM

11,624

0.60
±0.02
0.56
±0.03
0.84
±0.01
0.73
±0.20
0.80
±0.29
0.84
±0.01
0.93
±0.01
0.95
±0.01
0.97
±0.01

0.60
±0.03
0.54
±0.03
0.96
±0.03
0.30
±0.18
0.41
±0.40
0.74
±0.11
0.93
±0.07
1.00
±0.01
1.00
±0.00

0.66
±0.08
0.93
±0.02
0.72
±0.02
0.19
±0.31
0.16
±0.35
0.09
±0.02
0.06
±0.01
0.68
±0.02
0.62
±0.15

0.54
±0.09
0.17
±0.03
0.97
±0.03
0.84
±0.30
0.85
±0.34
0.99
±0.01
0.99
±0.01
1.00
±0.00
1.00
±0.00

0.62
±0.04
0.68
±0.03
0.82
±0.01
0.11
±0.10
0.04
±0.04
0.16
±0.03
0.10
±0.03
0.81
±0.02
0.75
±0.16

SVMUnblnc1
SVMUnblnc2
RFUnblnc1
RFUnblnc2
LSTMUnblnc1
LSTMUnblnc2

34,872
78,493
34,872
78,493
34,872
78,493

sents a model X trained on Unblnc1 dataset. Table 3.4 shows that LSTM maintains
high performance on both unbalanced datasets (LSTM-Unblnc1: precision=1.00, recall=0.68 and F1-score=0.81 and LSTM-Unblnc2: precision=1.00, recall=0.62 and
F1-score=0.75). The high performance of the LSTM model indicates that the temporal medication records in the unbalanced IBM MarketScan data encode critical
factors that provide an increased power to predict the development of SUD in adolescent ADHD enrollees, which were captured by the LSTM model.
Figure 3.7a illustrates the robustness of the LSTM model. The performance of the
LSTM model on both the training and the validation datasets remains stable when
different learning rates were applied. Figure 3.7b shows the model performance over a
wide range of number of hidden neurons, and Figure 3.7c shows how the variation of
the number of epochs affected the LSTM model performance. In both experiments,
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the LSTM model performance remained stable.
3.1.5

Hypothesis testing in longitudinal data using deep learning

To predict SUD from the temporal ADHD medication records X(P, T ), the LSTM
model were adopted. Besides the temporal ADHD medication records, each enrollee
has rich stationary features such as sex, ADHD initiation age, and medication type.
Such stationary features could be critical factors towards the development of SUD.
Two different approach were used here to test the functionality of the stationary
features. In the first approach, stationary features, including age and gender, were
encoded into the longitudinal ADHD medication records. In the second approach,
the IBM MarketScan data was separated using each stationary feature as a partitioning criterion, such as separating enrollees into age groups, changing the granularity
of the medication records, or ignoring medication-to-medication differences. Finally,
LSTM models were trained on these datasets and compared model performance. If
the model performance is significantly different than the model trained using complete data, then the selected enrollees regrouping criteria may be a critical factor
towards the development of SUD because it provides an increased power to predict
the development of SUD.
Note, an enrollee may be prescribed multiple medications at the same time point.
Cell x(i, j) in X(P, T ) is a vector of bits, each representing an ADHD medication and
a bit is 1 if the corresponding medication is prescribed. Since the LSTM requires the
input to be either a word or a value, the vector of bits were converted into an integer
and then apply the Min-Max normalization to vanish the effect of scaling and map
all values in [0, 1].
Knowing that in the temporal medication records there are critical factors that
increase the power to predict SUD in enrollees who initiate ADHD medication during
adolescence, the next step is to explore all of the important factors suggested from the
literature (such as age of ADHD medication initiation and demographic information).
To this end, demographic features, age and sex, as well as medication types were
encoded into the temporal medication records. Table 3.5 shows the performance of
a LSTM model trained only using the temporal pattern medication records (LSTMNoDemo) and a LSTM model trained using additional demographic features (LSTMDemo). As shown in Table 3.5, incorporating demographic features into the LSTM
model neither increased nor decreased the model performance significantly.
The effect of stationary features other than the demographic information, such as
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(a) Impact of the learning rate on the LSTM
model.

(b) Impact of the number of neurons on the
LSTM model.

(c) Impact of the number of epochs on the
LSTM model.

Figure 3.7: (a) The number of epochs is fixed to be 100. The learning rate varies
in a wide range. (b) The learning rate and number of epochs are fixed to be 0.09 and
100, respectively. The number of neurins is changed from 1 to 600. (c) The learning
rate and number of neurons are fixed to be 0.09 and 75, respectively. The number of
epochs is changed from 0.1 to 400.
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Table 3.5: Effect of encoding stationary features on the LSTM model performance
on predicting SUD.
Model

Size of
Data

LSTM
11,624
Demo
LSTM
11,624
NoDemo

Accuracy

Precision

Recall

Specificity F1Score

0.83
±0.01
0.84
±0.01

0.95
±0.04
0.96
±0.03

0.70
±0.03
0.72
±0.02

0.96
±0.04
0.97
±0.03

0.80
±0.02
0.82
±0.01

medication type, initiation age, sex, and temporal pattern of using medications on
developing SUD were further tested in this study. The IBM MarketScan data was
separated using each stationary feature as a partitioning criterion and then the LSTM
models were trained on the separated data and compared the model performance.
First, whether the medication application pattern is a key factor for predicting
SUD in adolescent ADHD enrollees was tested. Specifically, an enrollee may be prescribed a medication during a few months, stop for a few months and then start again
being prescribed the medication. To test whether the on-off medication application
pattern is a critical factor, a new dataset was generated by removing all the gaps from
the ADHD medication records, and trained a LSTM model called LSTM-NoGaps using the newly generated data. For comparison, another dataset was generated, in
which only the binary on-off medication application patterns were preserved. This
dataset is used to train a LSTM called LSTM-OnOf. Table 3.6 shows the performance of LSTM-NoGaps and LSTM-OnOf models.
Table 3.6 shows that the model performance of LSTM-NoGaps is significantly
worse than using the complete data. F1-Score drops from 0.81 to 0.53 when the gaps
were removed. However, the model performance of LSTM-OnOff is similar to the
LSTM model trained using the complete data. These results indicate that the on-off
medication application patterns encoded in the temporal data are a critical factor for
predicting the development of SUD in adolescent ADHD enrollees.
Second, duration of the medication application patterns was tested. Since in
the IBM MarketScan data the longest ADHD medication records span seven years,
a batch of new datasets was generated by only considering the ADHD medication
records in the first x years (x varies from 1 to 7). Note, all of these new datasets
include the same enrollees, but are across different ranges of time for their medication
records. Figure 3.8 shows LSTM results on these 7 datasets. In Figure 3.8, LSTMxyr represents a LSTM which is trained using the medication records in the first x
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Table 3.6: Effect of medication application patterns.
Model

Size of
Data

LSTM
11,624
NoGaps
LSTM
11,624
OnOff

Accuracy

Precision

Recall

Specificity F1Score

0.56
±0.01
0.84
±0.01

0.58
±0.06
0.98
±0.02

0.55
±0.21
0.69
±0.02

0.57
±0.21
0.99
±0.02

0.53
±0.11
0.81
±0.01

Figure 3.8: Impact of range of time of ADHD medication on SUD prediction.
When the medication record range is increased from one year to seven years, the
model performance increases.
years. Figure 3.8 shows that the F1-score of the LSTM-1yr model is low (average 0.48
and SD 0.27). However, the F1-score of the LSTM-2yr model increases significantly
from 0.48 to 0.58, and continued to increase when longer medication records are used.
These results indicate that the medication application patterns is a long-term pattern
(at least longer than one year).
Since the long-term temporal medication application patterns appears to be a key
factor in predicting subsequent SUD in adolescent ADHD enrollees, whether this association holds for different ADHD medication types or different sex groups was also
tested. The LSTM-Methylphenidate model is trained using enrollee’s data where
methylphenidate is the primary medication (≥ 80%). The LSTM-Amphetamine
model is trained using enrollees’ data where amphetamine is the primary medication. Table 3.7 shows that both models achieve a similar F1-Score (0.84 and 0.81)
compared to the LSTM model trained incorporating both medications (0.82). These
results indicate that long-term temporal medication application patterns exist using
different ADHD medication types, but the exact pattern may be different. Table 3.7
also shows LSTM-male and LSTM-female models achieve the same F1 score (0.80),
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Table 3.7: Performance of LSTM for adolescent ADHD enrollees with different
primary medication or sex.
Model
LSTM
Meth.
LSTM
Amph.
LSTM
Male
LSTM
Female

Size of
Data
2,076
4,834
8,468
2,824

Accuracy

Precision

Recall

Specificity F1Score

0.85
±0.03
0.84
±0.02
0.83
±0.02
0.82
±0.02

0.95
±0.03
0.97
±0.05
0.94
±0.07
0.90
±0.07

0.75
±0.04
0.70
±0.04
0.71
±0.05
0.73
±0.05

0.96
±0.02
0.97
±0.04
0.94
±0.07
0.91
±0.08

0.84
±0.03
0.81
±0.02
0.80
±0.02
0.80
±0.03

which is similar to the LSTM model trained incorporating both male and female enrollees (0.82). These results indicate that within different sex groups, the long-term
temporal medication application patterns constitute important factors captured by
the LSTM model.
Finally, the importance of the long-term temporal medication application patterns in different age groups was tested. Table 3.8 summarizes the LSTM model
performance when applied to different age groups. All the F1-Scores are similar to
each other and are similar to the F1-Score of the LSTM model trained using the
entire data. These results indicate that in different age groups, the long-term temporal medication application patterns constitute the important factors captured by the
LSTM model.
3.2

LSTM Prediction of MCI

Dementia is one of the most prevalent health problems in the aging population. It is
estimated that by 2030, 75.6 million people will suffer from various types of dementia
worldwide, and that this number will increase to 135.5 million people in 205069 . Such
an increase will place a tremendous burden on patients, their families, society, and
health care systems. Given that people with mild cognitive impairment are at an
increased risk for dementia, predicting MCI risk and understanding the progression
from cognitively unimpaired (CU) to MCI and dementia is a crucial task to help the
aging population with their health needs.
In general, MCI is formally determined by health professionals through a comprehensive cognitive evaluation, together with clinical examination, medical history and
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Table 3.8: Performance of LSTM for adolescent ADHD enrollees separated by age
group.
Model
LSTM
Age13
LSTM
Age14
LSTM
Age15
LSTM
Age16
LSTM
Age17
LSTM
Age18

Size of
Data
1,704
2,040
2,396
2,282
2,002
1,062

Accuracy

Precision

Recall

Specificity F1Score

0.81
±0.03
0.81
±0.03
0.82
±0.03
0.82
±0.04
0.82
±0.02
0.83
±0.04

0.87
±0.08
0.88
±0.04
0.92
±0.06
0.88
±0.10
0.89
±0.04
0.87
±0.08

0.74
±0.06
0.73
±0.04
0.70
±0.04
0.76
±0.06
0.74
±0.04
0.79
±0.07

0.88
±0.09
0.89
±0.04
0.93
±0.06
0.88
±0.12
0.91
±0.04
0.87
±0.10

0.79
±0.03
0.80
±0.03
0.79
±0.03
0.81
±0.03
0.81
±0.02
0.82
±0.04

often the input of an informant (an individual that know the patient very well) to
understand changes in cognition and daily function. However, this is not routinely
performed in many primary care visits which results in a delay of timely diagnosis, misses opportunities for appropriate care plans, and leads to adverse clinical
outcomes. Electronic health records (EHRs), especially clinical free text, contain
valuable information that is routinely recorded as part of clinical care. This rich
information may be used to identify patterns predicting the development of MCI and
dementia. Previous studies have shown that some signals of cognitive decline exist in
EHRs, years before the clinician diagnoses of cognitive impairment70, 71 .
Recently, deep learning models have demonstrated their capabilities in analyzing
EHR data72 . EHR data are a growing source of information that can be harnessed to
provide an earlier diagnosis and to identify those at greatest risk for developing MCI.
However, little is known about systematically analyzing patient data related to MCI
in routinely-collected EHRs and how their temporal patterns are associated with the
development of MCI. Although predicting MCI and understanding the progression
from CU to MCI utilizing EHRs is a challenging and largely unexplored task, deep
learning models can be used to capture temporal characteristics of patient data in
EHRs to predict early stages of MCI. In this study, the application of EHR data
analysis and deep learning models for predicting and clustering MCI patients has
been systematically studies.
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3.2.1

MCI prediction in the literature

Multiple studies to understand the progression from CU to MCI has been conducted.
In a study by Pankratz et al.(2015)73 demographic, clinical, and neuropsychological
measures implemented in Cox proportional hazard models were applied to predict
progression from CU to MCI. The authors showed that MCI risk factors presented
in their previous studies74–77 can be used to predict MCI using multivariate models.
They used the Mayo Clinic Study of Aging (MCSA) cohort78, 79 and developed an
augmented model capable of predicting progression from CU to MCI with AUC of
0.70. In a research conducted by Albert et al. (2018)80 , 224 CU participant were analyzed and followed up to detect measures or combination of measures that can be used
to predict MCI. These researchers analyzed various MCI risk factors from different
domains including cognitive, cerebrospinal fluid, magnetic resonance imaging (MRI),
and genetic domain. They utilized time-dependent receiver operating characteristic
and showed the feasibility of MCI prediction (best AUC using all variables > 0.83).
Another line of research is the prediction of dementia and understanding progression from MCI to dementia. Biomarkers, genetics, brain imaging as well as demographic and various variables related to individual’s lifestyle have been used in the
literature to predict progression from MCI to dementia with AUC ranging from 0.48
to 0.9181 . Further, clinical variables and primary care data have been analyzed using
logistic regression to predict progression of MCI to Alzheimer’s disease (AD) dementia82–85 . Ramakers et al.(2007)86 used general practice data to create risk prediction
models for dementia with sensitivity of 0.58 and specificity of 0.98 in the year before
diagnosis.
With the availability of public databases related to AD dementia, such as the
North American Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the European’s AddNeuroMed Stud, big data has been utilized in AD research the past couple
of years. Most of this research focused on diagnosing AD dementia, identify those at
greatest risk of MCI, and predicting progression from MCI to AD dementia. Much of
this work has utilized the non-community-based ADNI dataset and traditional machine learning models including support vector machines (SVMs), logistic regression
and random forest87 . SVM and linear models have also been used in the literature88
to discriminate patients with AD from MCI and CU patients in ADNI dataset. Moreover, SVMs have been utilized in separating patients with AD dementia or MCI from
CU patients using MRIs89, 90 , and predicting progression from MCI to AD dementia
using AddNeuroMed dataset91 . MRI images from ADNI data set has also been used

34

in a study utilizing deep learning models conducted by Li et al.(2014)92 . These results
show that convolutional neural network based deep learning models can detect AD
progression. In addition, neuroimaging, machine learning and deep learning has been
used to predict conversion from MCI to AD in ADNI93 . A comprehensive review of
applying big data prospective and machine learning models to advance AD research
is provided by Zhang et al. (2017)87 .
Multiple studies examined the progression from CU or MCI to dementia. However,
only a few studies considered progression from CU to MCI or MCI prediction using
patients EHR data. Often, MCI is not well recorded in EHR data because it is not a
clinical diagnosis per se, and thus there are not enough datasets suitable to train MCI
predictive models. In addition, discriminating CU patients from patients with MCI
is a very challenging task as MCI is the stage between the expected cognitive decline
of normal aging and the more serious decline of dementia94 . In this thesis, the abovementioned challenges are addressed and a potential of a deep learning model, coupled
with natural language processing is demonstrated, to extract MCI risk factors and
signals from unstructured EHRs and to predict onset of MCI. In addition, machine
learning and deep learning techniques are utilized to visualize and cluster patients
using EHR data and described a mechanism for EHR-based clustering.
3.2.2

Mayo Clinic Study of Aging Data

This study includes two main components: MCI prediction and patient clustering.
In MCI prediction, a long short term memory technique architecture is trained to
predict onset of MCI. In patient clustering, a denoising autoencoder is introduced to
better represent the patient data. The outputs of this denoising autoencoder were
visualized and clustered using t-SNE and K-means algorithms.
This study uses a longitudinal EHR data obtain from the Mayo Clinic Study on
Aging (n=5,923; 1,376 MCI). The MCSA is a prospective population-based cohort
study with comprehensive periodic cognitive assessment (at baseline and repeated
every 15 months), initiated in 2004 to investigate the epidemiology of MCI and dementia. Eligible subjects from the Olmsted County, Minn., population, were randomly selected and evaluated comprehensively in person using the clinical dementia
rating scale, a neurological evaluation and neuropsychological testing. A consensus
committee used previously published criteria to diagnose the participants with normal cognition, MCI or dementia. MCSA participants have follow-up visits every
15 months and have accumulated more than 23,000 visits to date. In the current
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analyses, only MCI patients who progressed from CU to MCI are included; i.e., the
patients who were diagnosed with MCI in their first visit are excluded from the study
to make sure the models are predicting initial MCI diagnosis. The MCSA cohort
mainly encounters Mayo Clinic, Olmsted County Medical Center, and Mayo Clinic
Health System for the regular healthcare. This study used clinical notes to automatically extract MCI risk factors and signals. To simplify the study, only patients
who have any notes at Mayo Clinic—i.e. are included, excluded patients who do not
have any clinical notes at Mayo Clinic during each visit interval. This reduced the
size of cohort (n=3,265; 558 MCI). Further, the patient data after being diagnosed
with MCI in MCSA were disregarded. Different types of data were used to predict
MCI: demographic information, diseases/disorders, and neuropsychiatric symptoms,
and activity of daily living (ADL). Table 3.9 contains a complete list of variables and
their EHR sources that were used to train the models.
Total 783,090 clinical notes were used to extract diseases/disorders, neuropsychiatric symptoms, and other types of data (Table 3.9). To extract variables from
clinical notes, the MedTaggerIE module in MedTagger95 was used, which is the opensource clinical natural language pipeline developed by Mayo Clinic for pattern-based
information extraction with a capability of assertion detection (i.e., negated, possible,
hypothetical, associated with a patient). Note, only non-negated variables associated
with patients were included.
3.2.3

MCI Patient Representation

The patients data were presented both in a temporal and static mode and used to
train a temporal model (LSTM recurrent neural network) and a static model (random
forest) for MCI prediction. To incorporate temporality, the data was converted into
a visit-time format X(V, T ), where V is patients' visits and T is the visit dates, each
visit vi includes all variables for a given visit listed in Table 3.9, and each date ti is
the relevant visit date. All of the patients' visits for a period of 5 years before their
first diagnosis dates for MCI patients and the latest visit for CU patients were used.
A 15-month sliding window was used for the past 5 years of history of visits to make
the temporal pattern asynchronous. Within each window an element-wise operation
was used to combine the visits within the window. Further, the patients data was
represented in a static mode to train the static model. In fact, instead of sliding a
15-month wide window, a 5-years window was used to cover the entire visit history of
patients. As a result, the longitudinal data was converted to a matrix Y (P, L), where
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Table 3.9: List of variables and their resources.
Variable Category

Variable

Source

Demographics

Age, Sex, Education

MCSA

Diseases / dis- Hypertension,
Atrial
fibrillation, Clinical
orders
Angina, Congestive heart failure, notes
Coronary artery disease, Myocardial
infarction, Coronary artery bypass
graft, Diabetes
Neuropsychiatric Delusion, Hallucinations, Agitation, Clinical
symptoms
Depression, Anxiety, Euphoria, Ap- notes
athy, Disinhibition, Irritability/lability, Motor behavior, Appetite/eating
change
ADL

Bathing, Dressing, Feeding, House- Patient
keeping, Responsible for own medica- provided
tion, Transportation, Toileting, Trans- information
ferring, preparing food

Others

Slow gait, cognitive complaint, im- Clinical
paired judgment/orientation, memory notes
concern, difficulty for concentrating,
difficulty for finance

P is the complete list of patients, each pi is a vector including variables described in
Table 3.9 and li is clinical diagnosis of MCI or CU of the patient pi .
3.2.4

Denoising Autuencoders

Denoising autoencoders96 have shown strong performance in efficiently representing
participants data97 . A four-layer denoising autoencoder was used in this study: an
input layer, two hidden layers (encoder and decoder layers) and an output layer.
Figure 3.9 shows the architecture of the network used in this study. The first hidden
layer encodes the input x and then the decoder decodes the encoded vector (see
Equation 3.2).

y = σ(W x + b)
z = σ(W 0 y + b0 )
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(3.2)

Figure 3.9: Architecture of the de-noising auto-encoder to represent patients using
EHR .
20 percent of the patient's information was corrupted and the corrupted information was plugged as x to Equation 3.2. The loss function is a mean squared error
of the output layer and the patient’s information before the corruption. Adam optimizer at a learning rate of 0.01 was performed for 300 epochs to optimize the loss
function. After training the autoencoder, all the samples were fed to the network
without corruption and the outputs of the first hidden layer (y) were considered as
a new representation for patient data. The new representation of data has lower
dimension (60 nodes were used for both of the hidden layers) and is less sparse. The
dimensionality of trained autoencoder's hidden nodes was further reduced using tSNE
for visualization and clustering purpose. K-means was used for clustering with k=5
as a default value because there are 5 potential clinical subtypes: 1) CU patients,
2) MCI positive- amnestic, single domain, 3) MCI positive- amnestic, multiple domain, 4) MCI positive- non amnestic, single domain, 5) MCI positive- non amnestic,
multiple domain.
3.2.5

Deep Learning prediction of MCI

The LSTM models were built under the Tensorflow platform98 and were trained
using two Tesla K80 GPUs. For systematic training and testing, a randomized cross
validation method was used to find optimal parameters. First, the data was randomly
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split into training (70 percent of data), validation (10 percent) and testing sets (20
percent). A stratified approach was used to split the data into train, validation
and test sets; the patients were split based on their age at the study entry to make
sure that different age groups are equally represented across training, validation and
testing datasets. Each time a set of parameters was randomly selected in a predefined
data pool; a LSTM model was trained on the training set and the model performance
was measured on the validation set. This process was repeated 100 times and the
best parameter set was selected based on the validation set performance. Then, the
best model (based on their performance on the validation set) was used to evaluate
prediction performance on the unseen test data.
Learning rates were randomly selected from [10−6 , 10−5 , 10−4 , 10−3 , 10−2 , 5−2 , 8−2 , 10−1 ].
The number of hidden neurons were selected from a wide range of integers which includes [10, 20, 40, 60, 80, 100, 140, 180, 200, 300, 600]. The batch size was set to be 2n
where n is an integer number in [5, 9]. The dropout probability was a random one
decimal float number (%.1f ) ranging from 0.3 to 0.7 and the number of iterations
were selected from [104 , 105 , 106 , 2 × 106 , 5 × 106 , 10 × 106 , 15 × 106 ].
Random forests served as a baseline. Parameters of the random forests model were
tuned using 5-fold cross validation. To search the hypothesis space, a random selection
of parameters in a predefined pool of possible parameters was utilized. Number of
estimators was a random integer number n × 100 where n is an even number in
[2, 20]. The same unseen test data as the one used in LSTM model was used to
evaluate the performance of the random forest model. It should be noted that random
forest models are trained on the static data and LSTM models are trained on the
longitudinal temporal data.
Performance of the LSTM and the random forest models are in Table 3.10. All the
results reported are on the test set. In Table 3.10, RF and LSTM respectively indicate
a random forest model and a LSTM model trained and tested on the original data.
RF over-sampled and LSTM over-sampled are the same models but trained using an
over-sampled training data and tested on the original test data; the population of
MCI patients was increased using a sampling with replacement approach.
In Table 3.10, the LSTM over-sampled produced both the highest F1-Score (0.46)
and ROC AUC (0.75). Both LSTM and LSTM over-sampled performed better than
the baselines in terms of F1 score. Both RF models produced higher accuracy than
LSTM models but their recall were much lower than LSTM models, showing that
random forest was biased due to the imbalanced class distribution (i.e., higher numbers of CU than MCI). These results indicate that LSTM models with temporal
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Table 3.10: Performance of MCI prediction using LSTM and random forest.
Model

Acc.

Prec. Rec.

F1-score

AUC

RF

0.82

0.44

0.13

0.21

0.73

RF Over-sampled

0.79

0.33

0.25

0.28

0.69

LSTM

0.73

0.33

0.59

0.43

0.71

LSTM Over-sampled

0.71

0.33

0.76

0.46

0.75

Table 3.11: Top 5 MCI risk factors detected by random forest.
Risk Factor
Age

Score
0.16

Hypertension

0.08

Education

0.07

Depression

0.06

Anxiety

0.05

patterns of the data might have increased capability in predicting MCI compared to
a traditional machine learning models using the static data.
In this study, the patients who were determined as MCI in their first visit to
the MCSA were excluded. When including those MCI patients at the first visit
(MCI=1,075), LSTM over-sampled produced higher performance than using the original data; i.e., precision, recall, F1-score and AUC were 0.53, 0.73, 0.61 and 0.74,
respectively. This increased performance might be because there are more signals of
patients who already had MCI before the first visit and/or the more data help create
the more efficient deep learning models.
The random forests was also used to investigate important risk factors for MCI.
Random forests have a capability to identify the important variables based on impurity using information gain; i.e., how much each variable contributes to decreasing
the impurity. Table 3.11 shows the top 5 variables based on their effect in decreasing
impurity. As can be seen from Table 3.11, age is the most important feature in discriminating between MCI and CU patients. Age, hypertension, education, depression
and anxiety have also been reported as important risk factors in developing MCI in
other literature85, 99–101 .
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3.2.6

Clustering and Visualizing MCI Patients

A denoising autoencoder with four layers was used to efficiently represent the patient
data addressing data sparsity and high dimensionality. Reduced dimensionality enables the patient data to map a more meaningful space for better clustering. The
outputs of the first hidden layer were mapped to a 2D space for visualization and
clustering using tSNE and K-means. Figure 3.10 visualizes the patient data. CU
patients are indicated by blue dots and MCI patients are represented by red dots.
Figure 3.11 shows the distribution of MCI versus CU patients. Notably, ratio
of MCI patients is much larger than the ratio of CU patients in cluster 2 but it
is opposite in cluster 4. This may indicate the potential of a deep learning model
for clustering distinct patient groups. Figure 3.12a shows the distribution of males
versus females and 3.12b further zoomed into males versus females for both CU and
MCI patients. As can be seen, cluster 0 mostly includes males; almost 50 percent
of males are clustered in this group. On the other hand, cluster 1 mostly includes
females; half of the female population is clustered within this group.
3.2.7

Deep Learning Prediction of MCI: Discussion

Despite the urgent need for early detection of MCI and dementia, there is a lack
of automated tool available to healthcare providers using routine EHR data. Given
that MCI is a precursor of dementia and could be a critical step in the prevention
and control of AD and other dementias, it is crucial to find a more efficient way to
determine MCI in its very early stages. This study addresses this issue by using
routinely-collected EHR data as part of patient care for predicting onset of MCI.
The LSTM RNN demonstrated its potential for MCI prediction incorporating
temporal patterns of patient data that were automatically extracted from EHRs. Although this study used limited set of MCI risk factors compared with the previous
study that used manually annotated variables, our models still produced comparable
(even slightly higher) performance. The LSTM RNN using longitudinal temporal
data seems to be more efficient in predicting MCI compared to using the traditional
machine learning models with static data. Machine learning techniques such as denoising autoencoders, K-means, and tSNE to visualize and cluster the patients EHR
data also showed a good potential to identify certain patient groups. The predictive model and patient clustering could (have the potential to) assist in the clinic to
support early identification of MCI patients as well as better characterization, determining more granular subgroups of MCI patients. This can enable tailored care plan
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Figure 3.10: Visualization of CU patients (blue dots) and patients with MCI (red
dots).

Figure 3.11: Distribution of MCI versus CU patients within each cluster. Y-axis
shows the ratio of CU or MCI population within the relevant cluster.
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(b) CU and MCI patients with their sex.

(a) male and female within each cluster.

Figure 3.12: Distribution of male and female patients within each cluster.
and open up new clinical practice opportunities using routine EHR data.
The limitation of this study includes the use of only Mayo clinical notes even
though participants enrolled in the MCSA visit other healthcare institutions, and
thus the patients might not be ideally represented by their comprehensive longitudinal
data. Use of EHR data from other institutions requires significant effort.
3.3

Conclusion

This chapter, described two studies: SUD prediction using LSTM and MCI prediction using LSTM. Both studies use the same deep learning framework. This proposed
model shows that LSTM models can capture the temporal patterns in big longitudinal data more precisely compared to traditional machine learning models. In the
first study, the long-term impact of ADHD medication initiated during adolescence
was systematically studied using the LSTM model. Long-term temporal medication
application patterns appeared to be key factors that provide increased power to predict the development of subsequent SUD in adolescent ADHD enrollees using deep
learning models. In the second study, LSTM RNN demonstrated a good potential
incorporating temporal EHR patterns to predict the conversion from CU to MCI.
When this model is combined with natural language processing to automatically extract MCI risk factors from EHR data, it could facilitate early detection of MCI
addressing a current significant delay and thus improve treatment plans and health
outcomes for patients.
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Chapter 4 Multi-stream Transformer

In this chapter, limitations of the recent models to analyze sequential data is provided. Then, a novel model is proposed to address these limitations. The proposed
model is designed to predict the onset of OUD using claims data. The motivations
behind proposing this new model and different components of the proposed model
are discussed to show how the proposed model can address previous limitations.
4.1

Introduction

Deep learning models are end to end algorithms that are constituted of nonlinear
components that each transform the representation at one level into a representation at an abstract level1, 102 . They already demonstrated great performance and
potential in analyzing sequential and longitudinal data8, 16, 43, 47 . Recurrent Neural
Networks were the variant of deep learning models that showed promising performance in natural language processing and has been heavily used in sequence labeling
and sequence to sequence modeling tasks. The sequential nature of RNNs and their
ability to deal with vanishing gradient problem and to memorize long dependencies in
input sequences, enables RNNs to tackle many issues in sequential and longitudinal
data analysis.
However, RNNs suffer from some limitations that precludes them from being
trained in a parallelized fashion and therefore performing well on more complex tasks
and inputs with longer sequences. Attention mechanism and later the transformer
models proposed to deal with the above mentioned problems of RNNs (refer to chapter
2). Given Transformers' demonstrated performance on various sequence modeling
tasks, transformer paradigms introduce exciting new opportunities for processing
sequential data. In this study, the technical and theoretical challenges in analyzing
multi stream longitudinal data using transformer models are addressed and a new
framework to analyze multi stream temporal big data is proposed.
There are several aspects of transformers that could be useful in analyzing multi
stream longitudinal data, such as their high performance in capturing long dependencies in input sequences, end-to-end learning scheme with integrated feature learning,
capability of parallelization within training examples. However, transformers are
originally designed for NLP tasks and the input to these models is typically a sequence of words. This causes some limitations in evaluating and using transformers
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in analyzing longitudinal data collected from multiple resources such as healthcare
data.
First, in spite of NLP data which are commonly sequential data the longitudinal
data is temporal. In fact, not only the order of events is important but also the time
gaps between the events plays a crucial role while processing data. For example,
earlier in this study is has been shown that temporal medication features, rather
than stationary features, are the most important factors for predicting SUD in the
IBM MarketScan data set. Therefore, instead of positional encoding of the order
of inputs at various time steps, a novel encoding should be encoded to capture the
temporal patterns of the longitudinal data and events rather than just the sequential
order. Second, the transformer is designed to attend to different words in a sentence
and find the relations between the words. In fact, input to the transformer is a single
stream of words while in many applications such as healthcare data analysis there are
multiple sources of inputs such as medications data, diagnoses data, and procedures
data. A more sophisticated model is needed to find the associations between different
input streams to capture hidden associations within and between the input streams.
Third, the attention mechanism in transformers can be utilized wisely to make the
deep learning models more transparent in applications such as biomedical applications
where finding the association between events (medications, diagnoses and procedures
in different visits) plays an important role and can make the process of decision
making more transparent.
All in all, this study proposes a new transformer based deep learning model to
tackle the above mentioned issues in processing longitudinal data with multiple input
streams. Next section describes the proposed model and explains how it can tackle
the above mentioned problems.
4.2

Opioid Use Disorder

Early identification and engagement of individuals at risk of developing an opioid
use disorder (OUD) is a critical unmet need in healthcare23, 24 . Individuals with
OUD often do not seek treatment or have internalized stigma about OUD that limits
identification through traditional means, such as screening and clinical interview25 .
Significant disparities limit access to treatment for OUD resulting in less than 20% of
all individuals with OUD receiving any form of treatment in the past year26 . While
there are currently tools developed to predict aberrant behavior when prescribing
opioids28 or to predict OUD from a general primary care population29 , there are only
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a few clinical tools, such as the Opioid Risk Tool30 , developed for assessing the risk of
OUD. Typical clinician workflow does not allow for comprehensive OUD screening,
but available administrative and clinical data have the potential to help clinicians
identify and screen higher risk patients providing an opportunity for primary care
professionals to play a greater role in increasing OUD detection, treatment, and
prevention.
Healthcare data are a growing source of information that can be harnessed together with machine learning to advance our understanding of factors that increase
the propensity for developing OUDs as well as those that aid in the treatment of the
disorders31, 32 . In healthcare data, patients’ outcomes and treatments are collected at
multiple follow-up times. Tools developed to analyze longitudinal healthcare data and
to extract meaningful patterns from these ever growing data are critical in addressing
real-world public health emergency including but not limited to OUD.
Analyzing real-world data is a complicated task with multiple computational challenges including high dimensionality, heterogeneity, temporal dependency, sparsity,
and irregularity1 . In particular, healthcare (and claim) data are typically collected
from multiple sources, and the subsequent data analysis requires simultaneous analysis of the temporal correlation among multiple streams such as medications, diagnoses, and procedures. Deep learning models have demonstrated great potential in
addressing some of these challenges and creating promising longitudinal healthcare
data analysis tools. Among them, Doctor AI8 , RETAIN9 , and DeepCare10 modeled
multiple data streams including medications, diagnoses, and procedures using Recurrent Neural Network (RNN) models such as Long-Short Term Memory models
(LSTMs)2 . Doctor AI concatenated multi-hot input vectors to predict subsequent
visit events8 . RETAIN used two separated RNNs to generate attentions at the visit
level and the variable level as well9 . These applications demonstrate that RNNs are
promising in longitudinal and sequential healthcare data analysis, since RNNs are
capable of extracting contextual information from past time steps and pass this information forward; this helps to efficiently model long-term dependencies in input
streams3 . Nevertheless, the network architecture and design preclude RNNs from
processing long streams in a reasonable amount of time4 . Attention mechanism was
introduced in RNNs to increase their capacity in capturing long range dependencies
more efficiently4–6 . Attention-based models bridge the gap between different states
in RNNs using a context vector. Successful applications of multiple attention layers
led to the transformer model7 , which removed recurrence in RNNs relying entirely on
the attention mechanism.
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The transformer is a type of attention-based deep learning models originally proposed for natural language processing (NLP) tasks such as machine translation7 .
Later, transformers have been applied on longitudinal EHR data11 to predict patients’ outcomes in the future. There are already several models that have been
successfully applied on EHR data without significantly changing the network architecture or loss12–14 . Of course, the typical transformer's structure can be altered
to better fit the special needs of solving healthcare problems11, 15 . Choi et al. proposed a transformer model for healthcare data analysis by utilizing the conditional
probabilities calculated from the encounter records to guide the self-attention mechanism in the transformer11 . BEHRT15 was developed based on BERT16 , a popular
transformer model for NLP tasks, for analyzing EHR data. BEHRT considers the
patients’ existing diagnoses and demographic data to predict their future diagnoses.
Similar to RNNs, transformers have been modified to model multiple data streams.
Li et al developed a two-stream transformer to analyze both time-over-channel and
channel-over-time features in human activity recognition tasks17 . Two parallel, yet
separate transformers were used to handle two input streams. Another multi-stream
transformer has been developed to generate effective self-attentions for speech recognition18 . They parallelized multiple self-attention encoders to process different input
speech frames. Gomez et al. developed a multi-channel transformer for sign language
translation using one self-attention encoder19 . Their model finds the attentions across
three different channels, i.e. hand shapes, mouthing, and upper body pose. A more
recent work20 showed that “transformer is all you need” by using multiple transformer
encoders. The encoded outputs can be concatenated using a joint decoder that enables simultaneous model training. There are also works that analyze multi-stream
data using transformer by simply stacking or parallelizing multiple transformer models21, 22 .
Although the recently developed transformer models showed promising performance, especially on handling multiple data streams, the potential of applying transformers on healthcare data analysis has not yet been fully explored. One of the
major limitations is the lack of capacity to model multiple data streams within the
self-attention layer. The transformer was originally designed to process one data
stream, which is mostly an order of words in a NLP task, at a time. The modified
transformers either can only handle multiple streams at intra-stream level or they are
not suitable to solve OUD identification problem as a real-time task where only previous clinical events can be used to make a decision at a specific time point. Here, OUD
identification is a complex data analysis task that includes not only finding long term
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effects of prescription opioids such as morphine and fentanyl, history of diagnoses
such as mood disorders, but also the hidden associations between patient’s prescriptions and diagnoses, since these input streams are highly correlated with each other.
Identifying the relationships within and between input streams may reveal hidden
patterns leading to an increased classification ability and interpretabilty for OUDs.
Moreover, the medication application patterns and the interactions between medications across different visits as well as the patient’s diagnoses patterns thorough
his/her medical history may carry important information that should be extracted in
order to develop precise and sensitive OUD identification tools.
This study proposes a novel transformer model called Multi-stream Transformer
for Predicting Opioid Use Disorder (MUPOD) to analyze longitudinal healthcare
data collected from multiple sources and predict the onset of OUD. First of all, MUPOD is capable of analyzing multiple data streams, such as medication and diagnosis,
simultaneously and extracting associations within and between the streams. Second,
MUPOD utilizes attention weights within and across data streams to interpret the
classification results. In the experimenst, MUPOD successfully captured the complex
associations within and between multiple streams including medications, diagnoses,
and demographic information, and predicts the onset of OUD precisely.
4.2.1

Data Set

The large-scale administrative records in the IBM (formerly Truven Health Analytics)
MarketScan Commercial Claims103 database were used to train and test both baseline
models and MUPOD. Data include person-specific clinical utilization, expenditures
and enrollment across inpatient, outpatient, prescription drug and carve-out services.
The database contains about 30 million enrollees, a nationally representative sample
of the US population with respect to sex (50% female), regional distribution, and age.
Medications, diagnoses and demographic information of 682,402 patients who have
at least one diagnosis of OUD (ICD-9: 304.0x, 305.5x and ICD-10: F11.xxx; where
x can be any code) from 2009 to 2018 were extracted. The hyper-geometric104 test
was used to identify sub-cohorts of OUD with high statistical significance of whether
a population consists the richest information of OUD. An OUD sub-cohort (p-value
0.00) with 229,214 patients who had at least one Clinical Classification Software code
(CCS) of 205 (patients with Spondylosis; intervertebral disc disorders; other back
problems) was identified. This sub-cohort was defined as the case cohort. Note that
CCS 205 has already been shown to be a prevalent diagnosis in OUD patients in the
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Figure 4.1: Data preprocesing schema for OUD prediction.
literature105, 106 .
The case cohort (OUD positive and CCS 205) was matched with a subpopulation
of OUD-negative patients called the control cohort. All the individuals in the control
cohort have the same back pain diagnosis (CCS 205) but do not develop OUD. Cases
and controls were first matched based on age and sex. The age of cases were divided
into 10-year bins and selected controls so that their age distribution matches the
age and sex distributions of cases. Second, they were matched based on the opioid
medication use duration. Specifically, every opioid medication were grouped with a
therapeutic class generic product identifier (TCGPI) of 65x as opioid medications.
Buprenorphine and Methadone were excluded as they are often used as a treatment for
opioid overdose. Next, OUD-negative patients who have the matched age and gender
with the case were randomly sampled ensuring that the averaged opioid use ratio
between case and control is almost equal. Figure 4.1 describes these preprocessing
steps.
Note, it is important that in OUD prediction applications the case and controls are
matched based on opioid medication use in addition to age and sex. Data visualization
was used to show the importance of matching cases and controls based on opioid
medication use. 1000 samples were randomly selected from each class and reduced
the dimensionality to 2D for visualization purpose using tSNE. Figure 4.2 shows the
distribution of OUD-positive (red dots) and OUD-negative (blue dots) in the data. In
Figure 4.2 cases and controls in the data are finely overlapped and distributed in the
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Figure 4.2: Distribution of OUD-positive and OUD-negative samples in the data.
Cases and controls are matched based on age, sex and opioid medication use.
feature space. In fact, the samples are a good representation for the discriminative
boundary between OUD-positive and OUD-negative patients. Therefore, the dataset
is a valid data to challenge our proposed model and baselines.
Table 4.1 shows the characteristics of cases and controls regarding age, sex, top-10
most frequent medications and top-10 most frequent diagnoses. For age, average age
were provided in each cohort as well as the standard deviation of the age within each
cohort. The numbers within parenthesis are the standard deviations. For sex, the
number of female patients is provided. The numbers within parenthesis in this case
are the percentage of female patients in each cohort.
The diagnoses and the medications were classified using CCS codes and Generic
Product Identifier codes (TCGPI) respectively. Opioid analgesics, anticonvulsants
(neuromuscular agents), musculoskeletal therapy agents, and antianxiety agents were
grouped based on the first two digits of their TCGPI codes as 65x, 72x, 75x, and
57x, respectively. The rest of medications were classified using the first 6 digits of
their TCGPI codes (from left to right). The variables presented in Table 4.1 have
already been reported as OUD risk factors in the literature105, 107 . Especially, diseases including “Other connective tissue disease”, “Other nervous system disorders”,
“Essential hypertension”, “Mood disorders”, “Other non-traumatic joint disorders and
Anxiety disorders” have been found to be more prevalent diagnoses among OUD patients than normal people105 . Note, since the case and control cohorts were matched
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based on age, sex and analgesics-opioid use, these three variables have similar statistical characteristics across both case and control cohorts. However, the distributions
of other variables vary across the case and control cohorts and can be utilized by
our deep learning models to discriminate OUD-positive patients from OUD-negative
individuals.
4.2.2

Data Pre-processing

For each of the enrollees in the case and control cohort, his/her medications and
diagnoses between Jan 2009 and Dec 2018 and demographic records were extracted.
In total, 78,136,935 medication records and 143,275,864 diagnoses records were extracted. The original format of the prescription and professional service encounter
claims in IBM MarketScan data is a table where each row is a visit and columns
are enrollee ID, date of visit, and prescription/diagnoses. If an enrollee has multiple
visits, each visit will occupy a row in the table.
To facilitate further study of the temporal patterns in the data, the data were
converted into an enrollee-time matrix X(P, T, F ) where each xi,j ⊆ F is a set of
medications or diagnoses (from feature space F ) associated with enrollee pi ∈ P at
time slot tj ∈ T , where P is the enrollee set and T is the set of monthly slots between
Jan 2009 and Dec 2018. Patients were excluded from X(P, T, F ) if the number of
valid entries is less than 3. As a result, the final dataset includes 392,492 patients
including equal number of OUD-positive and OUD-negative samples.
4.2.3

Patients Data Representation

Applying a temporal model on healthcare data is nontrivial due to technical challenges inherent in the data including high dimensionality, heterogeneity, temporal
dependency, sparsity, and irregularity1 . Therefore, patients data representation is
critical to ensure high model performance.
The goal of data representation is to learn a function: fR : X → Rd , where d
is 10 in this work and it shows the dimension of the representation to which each
input stream is mapped, X ∈ {M, D}, and M and D are medication and diagnosis,
respectively. To train the function fR , LSTM43, 45 was adopted. The outputs from
all LSTM hidden states were used to represent both the OUD case and control cohorts. The general schema of the data pre-processing and representation is shown in
Figure 4.3.
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Table 4.1: Distributions of age, sex, medication, and diagnoses in case and control
patients. Top 10 diagnoses and medications are provided. The numbers indicate the
number of patients who had at least one such diagnosis or medication.
Variables

Case

Control Variables

Case

Control

45.62
(13.81)

52.35
(14.39)

109,121 117,699
(55.60%) (59.98%)

Demographics
Age (SD)
Diagnoses
Code)

(CCS

Other connective tissue disease (211)

Female (percentage)
Medications
(TCGPI Code)

152,703 165,112 Analgesics - Opioid
(77.81%) (84.14%) (65)

190,141 196,246
(96.89%) (100%)

Other nervous system 138,866 141,350 Neuromuscular
disorders (95)
(70.76%) (72.03%) Agents Anticonvulsants (72)

105,508 97,444
(53.76%) (49.65%)

Essential
sion (98)

106,186 102,888
(54.11%) (52.43%)

hyperten- 106,299 132,049
(54.17%) (67.29)

Musculoskeletal
Therapy Agents (75)

Mood disorders (657)

97,035
81,306
Antianxiety
(49.45%) (41.43%) (57)

Agents

76,830
75,463
(39.15%) (38.45%)

Other aftercare (257)

127,131 133,920 Proton Pump In- 71,243
86,561
(64.78%) (68.24%) hibitors (492700)
(36.30%) (44.11%)

Residual codes; un- 136,177 152,748 Serotoninclassified (259)
(69.39%) (77.83%) norepinephrine
Reuptake Inhibitors
(581800)

58,039
48,323
(29.57%) (24.62%)

Other non-traumatic 134,042 150,660 Selective Serotonin
joint disorders (204)
(68.30%) (76.77%) Reuptake Inhibitors
(581600)

69,665
65,005
(35.50%) (33.12%)

Anxiety
(651)

disorders

Disorders of lipid
metabolism (53)

91,736
78,296
Hmg Coa Reductase 53,806
79,201
(46.75%) (39.90%) Inhibitors (394000)
(27.42%) (40.36)
94,507
122,322 Non-barbiturate
(48.16%) (62.33%) Hypnotics (602040)

46,965
44,404
(23.93%) (22.63%)

Medical
examina- 129,224 147,268 Nonsteroidal
Anti- 87,301
98,639
tion/evaluation (256) (65.85%) (75.04%) inflammatory Agents (44.49%) (50.26%)
(661000)

52

Figure 4.3: Data preprocessing and patient representation. EHR data are first
converted to an enrollee-time matrix X(P, T, F ). Then, the data are fed to LSTM
models to encode the medication and diagnosis streams separately.
4.3

MUPOD: Two-stream Transformer

MUPOD is a transformer-based deep learning model designed to analyze n highly
correlated healthcare data streams simultaneously. To minimize ambiguity, the algorithm is described for a single patient and for n = 3. Each patient can be represented
by p = (S, y) in which S is a set of input streams and y is the target label. Herein,
three input streams are considered: 1) medication tuples (T, M ) in which ti is the ith
time step and M is a list of medications that the patient is prescribed with at time
ti , 2), diagnoses tuples (T, D) where ti is the ith time step and D is a list of diagnoses
assigned to the patient P at time ti , 3) demographic tuples (T, G) in which ti is the
ith time step and G is the demographic information of patient P at ti .
This study uses the encoder part of transformer to identify the associations between medication and diagnosis across time and detect the onset of OUD. Medications
M , diagnoses D, and demographics G are fed to the model in parallel. The first step
is to incorporate the temporal patterns of the data stream into the encoder’s inputs
using positional encoding. The embedding layer in the transformer is replaced by
the proposed LSTM based representation layer. This change has two computational
advantages. Firstly, it deals with challenges in the input data such as variable dimension and data sparseness, which is common in longitudinal healthcare data. Secondly,
it extracts hidden parameters and transforms the original input into a new feature
space where cases and controls are better separated than in the original feature space.
The encoded input streams are plugged into the attention layer to generate Query,
Key, and Value matrices for each input stream. For example, medications M are fed
to a set of fully connected layers to generate MQ , MK , and MV , representing the
query, key, and value matrices for the encoded medication stream for patient P . Let
X, Y ∈ {M, D}, the Query, Key, and Value matrices are used to find the attentions
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(a) General architecture of MUPOD.

(b) Multi-stream encoder.

Figure 4.4: MUPOD architecture. XQ , XK , and XV represent query, key, and
value matrices for the input stream X, where X ∈ {M edication, Diagnoses}. AttXY
represents the attention weights between different records across input streams X and
Y , where X, Y ∈ {M edications, Diagnoses}. OXY represents the outputs, which
capture the associations between the input streams X and Y . The demographic
information is plugged into the system before the last layer and in the classification
layer.
across these three input streams:
XQ Y >
Attention(XQ , YK , YV ) = sof tmax( √ K )YV
dk

(4.1)

Note, the dk is the same as the original transformer. Figure 4.4a describes how the
data flows through the different layers of MUPOD. The raw medication and diagnose
streams are first represented in the representation layer (the intermediate outputs of
the LSTMS models in Figure 4.3). The temporal information is then encoded into
the represented streams in the temporal encoding layer. The encoded streams are
processed in the MUPOD’s multi-stream encoder layer. This novel multi-attention
layer is further described in more details in Figure 4.4b. In the figure, XQ , XK ,
and XV represent query, key, and value matrices for stream X (X ∈ {M, D}). All
possible combinations of the streams are used to determine the attention weights
between different visits and across streams. Attentions are then passed through a set
of dense layers to generate outputs. For example, given two data streams M and D,
three combinations can be generated i.e. M M , M D, and DD.
The reconstruction layer receives the relevant outputs and maps them to appropriate format for the next layer as described in Equation 4.2. For example, only
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the outputs relevant to the medications (M ) including OM M and OM D are used to
reconstruct the medication stream appropriate to be fed into the next encoder layer:
f : OXX , OXY −→ X̂
X̂ =[Concat(OXX , OXY )]Wx + bx

(4.2)

where OXX , OXY ⊂ {OM M , OM D , ODD }, X̂ ∈ {M̂ , D̂}, X, Y ∈ {M, D}, Wx and bx
are trainable reconstruction weight and bias matrices. The two reconstructed matrices
generated by the last encoder layer are fed to classification layer to make the final
decision for the current patient p as Sof tmax([Concat(M̂ , D̂)]W + b).
4.3.1

Experimental Results

All the deep learning models in this work were deployed on the TensorFlow platform65
and were trained using eight GeForce GTX 1080 GPUs. The original transformer
model, LSTM models, Linear Regression (LR), Random Forest (RF)67 and Support
Vector Machine (SVM)66 were compared with MUPOD as baselines. 314,504 samples
were used for training, 38,776 samples for validation and 39,212 for testing the models.
All results reported in this paper are on the test set. All models were optimized using
a random search policy across hyper-parameters of each model. A grid of hyperparameters values was set up and 10 random combinations of the hyper-parameters
were selected to train the models.
The optimized SVM model uses a RBF kernel function and the optimum value
for the parameter C is 0.0039 in this model. The optimized linear regression model
uses the L2 norm with C = 0.0625 in penalization and the sag algorithm as it's solver
method. The optimum number of trees in the random forest model is 1600 and the
optimum value for maximum number of levels in a tree is 40. For the LSTMs, their
learning rates were randomly set to 10n where n ∈ {−2, −3, −4}. The batch size was
randomly selected from {64, 256, 512} and the number of iterations was randomly
selected from n × 103 where n ∈ {10, 50, 100, 200}. The regularization parameter for
LSTM models was randomly selected from 10n where n ∈ {−4, −5, −6}. The number
of hidden neurons for the LSTMs in the representation layer was fixed to 10; because
the outputs of these LSTM models were the inputs to MUPOD and the inputs to
our model have to be of a fixed dimension (the dimension of our model in this paper
is 20: 10 for medications and 10 for diagnoses stream). However, the number of
hidden neurons for the other LSTM model used as a baseline (refer to Table 4.2) was
randomly selected from 2n where n ∈ {3, 4, 5, 6, 7, 8}.
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Table 4.2 compares the classification performance of MUPOD with LR, RF, SVM,
LSTM and the original Transformer model. The same train, validation and test data
were used to train, validate and test all models in Table 4.2 except for the SVM
model. Due to the hardware and time limitation this model was trained and tested
using 10,000 randomly selected samples. Note, the LSTM model in Table 4.2 is
trained using medication, diagnosis and demographic data. The vectors of medication, diagnosis and demographics were concatenated in each time step and formed a
single vector which was fed to this LSTM model. The LSTM model were dynamically
unrolled based on the input sequences' lengths and applied a fully connected layer
and an argmax function on the last output of the unrolled LSTM model to make the
final decisions. The hyper-parameter search space for this LSTM was the same as
explained earlier in this section.
A randomized 5-fold cross validation was used to tune LR, RF and SVM models.
The LR, RF and SVM were trained on the static data and the LSTM, transformer
and MUPOD were trained on the longitudinal data. To create static data for LR,
RF and SVM, the longitudinal data was converted to a new format Y (P, L), where P
is the complete list of patients, and L is a vector including aggregated values for all
medication, diagnosis and demographic features across time steps (from Jan. 2009 to
Dec. 2018). In fact, the frequencies for each medications and diagnoses were counted
and concatenated with demographic information of the patients to create L.
Transformer is the original encoder block of the transformer model7 . The vectors
of medication, diagnosis and demographics were concatenated and fed to the original
encoder block of the transformer model. Then, a fully connected layer and softmax
function were used to perform the final classifications. In Table 4.2, MUPOD has
the highest accuracy (0.775), precision (0.741), F1-score (0.790) and AUC (0.871).
These results indicate that our proposed model captures important factors in the
medication, diagnosis and demographic data and provides an increased power to
detect the development of OUD, while LR, RF, SVM, LSTM and original Transformer
appear to miss such factors.
In addition, the models' performances were tested on three imbalanced test data
sets with the ratio of OUD-positive samples to OUD-negative samples set to 0.1, 0.2
and 0.5. OUD is an uncommon event and the ratio of OUD-positive to OUD-negative
patients in patients who have used Opioid prescriptions at least 3 times is 3.2% in
the data set. Therefore, the experiments in Table 4.3 were conducted to simulate
the performance of the models on imbalanced datasets as well. Table 4.3 shows the
model performances on imbalanced test sets. Table 4.3 shows that MUPOD maintains
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Table 4.2: Performance of OUD classification using MUPOD compared to RF, SVM,
LSTM and original transformer.
Model

Acc.

Prec.

Rec.

F1score

AUC

P@R=.8±0.001

LR

0.638

0.641

0.625

0.633

0.689

0.463

RF

0.698

0.693

0.710

0.702

0.774

0.449

SVM

0.569

0.539

0.831

0.654

0.677

0.478

LSTM

0.693

0.784

0.533

0.635

0.790

0.666

Transformer

0.708

0.654

0.880

0.751

0.801

0.689

MUPOD

0.775

0.741

0.847

0.790

0.871

0.771

Table 4.3: OUD classification results for imbalanced test sets. The .xN means the
number of samples in the OUD-positive cohort are 0.x times smaller than the number
of samples in the OUD-negative cohort.
Model

Precision
.5N .2N .1N

RF
.531 .313 .182
LSTM
.539 .312 .189
Transformer .486 .276 .160
MUPOD
.588.364.221

Recall
.5N .2N .1N

F1-score
.5N .2N .1N

AUC
.5N .2N .1N

.710 .715 .701
.548 .532 .546
.879.885.883
.845 .848 .843

.608 .436 .290
.544 .393 .281
.626 .420 .270
.693.509.351

.773 .777 .770
.730 .723 .732
.799 .804 .796
.871.870.871

higher performance on all imbalanced test sets compared to all baselines in terms of
precision, F1-score and AUC. Note, the accuracy is not presented in Table 4.3, because
this measure is not informative when assessing algorithms on imbalanced data.
The relationships between the medication and diagnosis streams were examined
by aggregating the attention weights in the first layer of the model for all the records
of each individual and visualized the results. While it is still unclear whether attentions can be used to explain deep learning models108, 109 , attention weights have
been used extensively to assess feature importance15, 110 . In particular, the aggregated attentions across all the records of the same patient may be useful to identify
important relationships between his/her prescriptions and diagnoses. In the visualization, a rectangular node represents a medication type and an oval node represents
a diagnosis code. The accumulated attention weights were divided to “moderate”
and “strong” based on pre-defined thresholds (i.e. moderate: 0.3 ∼ 0.6, and strong:
> 0.6) that were selected by visually inspecting the distribution of accumulated attention weights. The moderate and strong connections are represented using dashed
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and solid lines respectively. The lines of an OUD-negative patient are colored black,
while the lines of an OUD-positive patient are colored red.
Figure 4.5b shows the attention weights computed with MUPOD on one OUDpositive and one OUD-negative patient. The cosine similarities of the medication
and diagnosis streams of the two patients are 0.85 and 0.27, respectively, indicating
that they have different diagnoses but similar medication records. The connections
belonging to the positive and negative patients are well separated. Besides, almost
all the strong connections are from the OUD-positive patient, while all the moderate
connections are from the OUD-negative patient.
Similarly, Figure 4.5c shows the attention weights on one OUD-positive and
one OUD-negative patient. The cosine similarities of the medication and diagnosis
streams of the two patients are 0.71 and 0.93, respectively, indicating that they have
very similar diagnoses and medication records. Although they have similar records
and similar connections between medication and diagnoses nodes, the strengths of
attention are different for the OUD-positive patient versus the OUD-negative patient
and MUPOD was able to correctly classify these two samples. Note that ONTJD and
Opioid are collected with both the OUD-positive link (red) and the OUD-negative
link (black), indicating the ONTJD-Opioid is often observed on both cases. Figure 4.5 shows that the attention weights in MUPOD can be used to: 1) discriminate
OUD-positive from OUD-negative patients and 2) reveal the relationships between
medications that the patient has been prescribed with and the diagnoses he/she has
been diagnosed with. These attention weights can further be accumulated across all
patients in the cohort to create more generalized conclusions and OUD risk factor
identification.
4.4

MUPOD: Multi-stream Transformer

In this section, a multi-stream transformer is proposed and developed to predict
OUD onset among patients in IBM MarketScan data. This proposed multi-stream
transformer extends the two-stream transformer described in the previous section in
multiple ways:
• The multi-stream transformer is capable of analyzing more than two streams of
data. In fact, it is capable of simultaneously processing demographics, medications, diagnoses and procedures.
• The multi-stream transformer is trained using a much larger cohort. This model
58

(b) A pair of OUD-positive
and OUD-negative samples
(c) A pair of OUD-positive
that have different diagand OUD-negative samples
(a) Medication and diagnoses noses but similar medication that have very similar diagabbreviations and full names. records.
noses and medication records.

Figure 4.5: Attention weights. Rectangular nodes represent medications and oval
nodes represent diagnoses. Solid, dashed and dotted edges respectively mean strong,
moderate and weak connections. Abbreviations were used for medications and diagnoses, and the full names are provided in (a).
is trained and tested using all patients in IBM MarketScan data who have been
prescribed with a certain amount of opioid.
• Further, this model uses all available medications, diagnoses and procedures
instead of the top-20 features which was used to train two-stream transformer.
In fact, the model is trained with 50 high level medications, 138 CCS diagnoses
codes, 80 procedure CCS codes and 2 demographics variables. These features
are selected after performing a sparse feature filtering originally performed on
more than 600 features.
• The prediction window size increased from 1 month to 6 months.
• An open source tool is released to efficiently process big claim data sets and is
available for other researchers to use the multi-stream transformer.
4.4.1

Cohort Selection and pre-processing

The cohort selection for multi-stream transformer is more comprehensive compared
to the cohort selected to train and test the two-stream transformer. Here, the patients
who have been prescribed with Buprenorphine or Methadone are also considered as
cases as the prescriptions of these two medications is a strong indication of OUD.
The cohort selection to choose case samples in this study can be described as:
• At least one OUD diagnoses or one prescription for Buprenorphine or Methadone.
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• At least 3 opioid (other than Buprenorphine and Methadone) prescriptions 180
days prior to OUD diagnoses date.
• At least 12 month of data availability.
The cohort selection for controls can be described as:
• Never been diagnose with OUD or been prescribed with Buprenorphine or
Methadone.
• At least 3 opioid (other than Buprenorphine and Methadone) prescriptions 180
days prior to their last record in the data.
• At least 12 month of data availability.
This process resulted in 7,910,707 OUD-negative and 257,084 OUD-positive patients. These cases and controls were matched based on multiple criteria: 1) age, 2)
gender, 3) the opioid use duration, and 4) the data availability. However, due to the
large volume of the data (more than 1M patients data over 10 years and with more
than 600 variables at each time step) the matching can not be (efficiently) directly
applied. Therefore, an anchor-based method was used to perform the matching. The
OUD-positive cohort was first divided into tow sub-cohorts based on the patients' genders. Each sub-cohort is then clustered using K-means algorithm. Elbow method was
used to define the number of cluster for each sub-cohort. Figures 4.6 and 4.7 shows
the results of the elbow method applied to find the optimum number of clusters on
male patients and female patients, respectively.
Then, cluster centers as well as one percent of the data points in each cluster were
used as anchors and cases and control samples were matched based on their distance
to these anchors. Figure 4.8 shows the distribution of a sample of cases and controls
after matching was performed. Red dots represent OUD-positive cases and blue dots
represent OUD-negative controls. The cases and controls are well matched as their
distance is close to each other in the 2D space created by the tSNE algorithm.
Here, the medications are grouped using the first two digits of the TCGPI codes,
the diagnoses variables are grouped using CCS code, and the procedures variables are
grouped using procedure CCS codes. As a result, each record includes 94 medications,
284 diagnoses and 243 procedures. Including the demographic features (age and sex)
the total number of features in the data is 623 features. Figures 4.9, 4.10 and 4.11
respectively describe the frequencies for medication, diagnosis and procedure features
in the cohort. In these figures, the x axis shows the features like fi and the y axis
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Figure 4.6: Elbow diagram results for OUD-positive male patients. The optimum
number of clusters is 10.

Figure 4.7: Elbow diagram results for OUD-positive female patients. The optimum
number of clusters is 11.
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Figure 4.8: tSNE visualization of OUD-positives and OUD-negatives.

Figure 4.9: Distribution of medication features frequencies.
shows the number of patients for whom the frequency of occurring fi is larger than
zero.
To reduce the sparsity of data and due to hardware limitations, the features outside of the mean plus two standard deviations of the distributions were excluded from
the feature space. This reduced the number of features from 623 to 270 features (50
medications, 138 diagnoses, 80 rocedures and 2 demographics). Similar to the process described in Figure 4.3, the LSTM models were used to represent patients' data.
However, since this study included procedures in addition to medications and diag62

Figure 4.10: Distribution of diagnosis features frequencies.

Figure 4.11: Distribution of procedure features frequencies.
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noses, an extra LSTM model was trained for procedures stream as well. Note, the
LSTM for representing medications and diagnoses were re-trained too as the cohort
and features are changed in this study. The represented medications, diagnoses and
procedures were then used to train a multi-stream transformer model described in
the following section.
4.4.2

Multi-stream Transformer

The model proposed in this study is a transformer based model to analyze temporal
claims data. Each patient can be represented by P = (S, y) in which S is a set of input
sequences and y is the target label. Here in, three input sequences are considered
as a common approach in healthcare data analysis: 1) medications tuples (ti , Mi ) in
which ti is the ith time step and Mi is a list of medications that the patient used (is
prescribed with) at time ith , 2) diagnoses tuples (ti , Di ) where ti is the ith time step
and Di is a list of diagnoses that have been assigned to the patient P at time ti , 3)
procedures tuple (ti , Pi ) in which ti is the ith time step and Pi is a list of procedures
that patient P has gone through at time ti . The opioid use disorder is considered as
an example application of the proposed method in this study and therefore the label
yi defines if the patient Pi is diagnosed with OUD or not. Figure 4.12 shows the
high-level overview of the proposed model.
Medications M , diagnoses D, and procedures P are fed to the model at the same
time and in parallel. The first step is to incorporate the temporal pattern of the
visits into raw inputs. The encoded input sequences are plugged into the Attention
layer which is the most important component of the proposed model. This layer
first uses fully connected network to generate query, key and value matrixes for each
of the input streams. For example, medications M are fed to the fully connected
layer to generate MQ , MK , and MV which are query, key, and value matrixes for the
medications stream for the patient p. These query, key, and value matrixes are used
to find the attention weights across different input sequences using 4.3.
XQ Y >
Attention(XQ , YK , YV ) = sof tmax( √ K )YV
dk
W here X, Y ∈ {M, D, P }

(4.3)
(4.4)

Figure 4.13 describes how the attention weights are calculated across different
input streams and converted to new outputs for the next encoder layer. In figure
4.13, XQ , XK , and XV represent query, key, and value matrixes for input stream
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Figure 4.12: General architecture of the multi-stream transformer model.
X, where X ∈ {M, D, P }. All possible permutations of the input streams is used
to find the attention weights between different visits and across different input sequences; medications, diagnoses, and procedures. Attentions are then passed through
a dense layer to generate outputs. In this application, there are three input streams
(medications, diagnoses, and procedures), and this leads to six permutations (M M ,
M D, M P , DD, DP , P P , where M , D, and P represent medications, diagnoses, and
procedures, respectively).
Reconstruction layer gets relevant output and map them to appropriate format
for the next layer as described in 4.5. For example, only the outputs relevant to
the medications (M ) including OM M , OM D , and OM P are used to reconstruct the
medication stream appropriate to be fed into the next encoder layer. The three
reconstructed matrixes generated by the last encoder layer are fed to a prediction
layer to make the final prediction for the current patient p. The prediction layer is
implemented in 4.6.
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Figure 4.13: Self attention layer of the multi-stream transformer. Proposed modeloutput calculation across medications, diagnoses, and procedure. XQ , XK , and XV
represent query, key, and value matrixes for input stream X, where X ∈
{M edication, Diagnoses, P rocedures}. AttXY represents the attention weights between different visits of patient P and across input streams X and Y , where
X, Y ∈ {M edications, Diagnoses, P rocedures}. OXY represents the outputs
which captures the association between input streams X and Y , where X, Y ∈
{M edications, Diagnoses, P rocedures}.

X̂ = f (OXX , OXY , OXZ )
f : OXX , OXY , OXZ ⊂ {OM M , OM D , OM P , ODD , ODP , OP P } −→ X̂
where
X̂ ∈ {M̂ , D̂, P̂ } and X, Y, Z ∈ {M, D, P }
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(4.5)

P rediction = g(M̂ , D̂, P̂ )
g : M̂ , D̂, P̂ −→ P rediction
where
g(M̂ , D̂, P̂ ) = [Concat(M̂ , D̂, P̂ )]W + b

(4.6)

In which, average is an element-wise averaging function, W and b are trainable weight
and bias matrixes to generate the last predictions.
4.4.3

Multi-stream Transformer: Results

The proposed multi-stream transformer was trained and tested using 474,208 patients' data over 12 years (2009-2020). The feature set at each time step include 270
medications, diagnoses , procedures and demographics features. Logistic regression,
random forest, LSTM and the encoder part of the transformer model with a fully connected layer on top of it were used as baselines. 90 percent of the data was used for
training and validation and all models were tested on the same unseen test set which
included 10 percent of the data selected randomly. The classical machine learning
models (random forest and logistic regression) were fine tuned using a randomized
cross validation. However, deep learning models were only trained once due to high
time and hardware complexity and their performance on the test set are reported.
Table 4.4 compares the performance of the deep learning models including the
multi-stream transformer model with the classical machine learning models. Deep
learning models show a better performance in predicting OUD 6 months before the
onset of this disorder. Among the deep learning models, multi-stream transformer
predicts OUD with higher recall, F1-score and AUC. This results show that the
proposed multi-stream transformer can generally be more accurate and efficient in
predicting OUD 6 months prior to the onset of OUD and using 270 features.
Further, the performance of the models were tested on three imbalanced test sets
with OUD-positive population size to OUD-negative population size ratio being 0.5,
0.2 and 0.1. Table 4.4 shows the performance of logistic regression, random forest,
LSTM, single-stream transformer and multi-stream transformer on these imbalanced
test sets. Note, the models are trained on the balanced train set. The prediction
performance of the models drops as the test set becomes more imbalance. However,
the multi-stream transformer still has the highest AUC and recall compared to the
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Table 4.4: Performance of OUD classification using multi-stream transformer compared to RF, SVM, LSTM and original transformer.
Model

Acc.

Prec.

Rec.

F1score

AUC

LR

0.609

0.630

0.519

0.569

0.651

RF

0.631

0.624

0.650

0.637

0.679

LSTM

0.668

0.648

0.738

0.690

0.732

Single-stream
transformer

0.651

0.603

0.874

0.713

0.725

Multi-stream
transformer

0.652

0.602

0.890

0.718

0.742

Table 4.5: OUD classification results for imbalanced test sets. The .xN means the
number of samples in the OUD-positive cohort are 0.x times smaller than the number
of samples in the OUD-negative cohort.
Model

Precision
.5N .2N .1N

LR
.460
RF
.454
LSTM
.457
Transformer .431
MUPOD
.430

.254
.247
.250
.232
.230

.146
.145
.147
.132
.132

Recall
.5N .2N .1N

F1-score
.5N .2N .1N

AUC
.5N .2N .1N

.518
.651
.718
.872
.888

.487
.535
.559
.577
.579

.650
.679
.706
.724
.741

.517
.644
.712
.870
.883

.522
.663
.733
.872
.897

.340
.357
.371
.367
.366

.229
.237
.245
.229
.230

.651
.675
.704
.721
.737

.655
.686
.716
.724
.746

other models. LSTM and logistic regression also showed good performance in some
cases in terms of precision and F1-score.
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Chapter 5 Discussion

In this thesis, multiple deep learning based models were proposed to analyze longitudinal claims data collected from multiple sources. The first proposed model was
a LSTM based framework to analyze claims and EHR data, and create disease prediction tools. This model addresses the challenges in analyzing temporal claims data
such as sparsity, class imbalance problem, and temporal dependency. This framework has three main components: 1) data pre-processing which convert the data set
format into an appropriate input format for recurrent neural networks training, 2)
disease prediction using LSTM models, 3) hypothesis exploration by varying model
and its inputs. The proposed framework was used to perform disease prediction on
substance use disorder and mild cognitive impairment. In the first case, IBM MarketScan claims data was used and in the latter study, the Mayo Clinic Study of
Aging Data was used. LSTM models in the proposed framework performed better in
predicting these diseases compared to classical machine learning in both cases.
However, recent advances in deep learning has shown the inefficiency of recurrent
neural networks in terms of computational performance and accuracy in processing
long sequences. This problem is originated in the sequential nature of recurrent neural
networks. Factorization techniques111 , attention based models5, 6 , and transformers7
were proposed to improve computational efficiency and the RNN' performance in analyzing longer sequences. The transformer based models was proposed entirely based
on attention mechanism and removed the sequential nature of RNNs. These models
outperformed state of the art deep learning models in almost all of sequential data
analysis tasks. However, transformers were generally developed for natural language
processing tasks and originally designed to analyze a single sequence of words.
Here, the predictive modeling capabilities of the transformer was compared with
LSTMs and traditional machine learning in OUD prediction. Further, a novel transformer based model was proposed to efficiently apply them on longitudinal claim
data. The transformer was traditionally designed to analyze a single sequence of
words. The proposed transformer in this thesis offers a more efficient model to analyze multiple sequences. In fact, the proposed model extracts the associations within
and across different sources of patient information including medications, diagnoses,
and procedures.
The proposed transformer is designed to simultaneously analyze multiple types
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of healthcare data streams, such as medications and diagnoses, by attending to segments within and across these data streams. This model along with a single stream
transformer and classical machine learning models such as random forest and logistic regression were trained on more than 470K patients' data including 270 medications, diagnoses, procedures and demographics in one experiment, and on 390K
patinets' data including 22 medications, diagnoses and demographics features in another experiment. In both experiments the deep learning models and especially the
proposed multi-stream transformer performed better in predicting opioid use disorder. The experimental results conducted in this thesis shows that the proposed
multi-stream transformer is an efficient model that is capable of predicting opioid use
disorder from 1-6 months before the onset of this disorder significantly better than
the traditional models and recently developed deep learning models. Further, the explainability of the proposed model was investigated and it showed that the attention
weights computed by the multi-stream transformer can be utilized to provide some
explanations on the predictions provided by the model.
5.1

Limitations

There are some limitations in this thesis that need to be considered before using
the proposed models. Although the proposed multi-stream transformer uses a thorough history of medications, diagnoses, procedures and demographics information of
patients, there are other aspects of patient information that can help boost the prediction performances. For example, the opioid dosage which is typically measured by
Morphine Milligram Equivalent (MME), can be utilized to increase the performance
of the models. The MME can be incorporated as a parallel signal along with medications, diagnoses and procedures or it can be added to the system in the last layer
when the model is performing the final predictions. Second, the explainability of
the proposed model was explored using a few representative samples. These samples
could show how the multi-stream transformer can discriminate OUD-positive samples
from OUD-negatives and provided intuitions in how medications and diagnoses are
related for those patients. However, these attentions cannot be used to infer causal
associations.
Another limitation of this thesis is that the models are trained and tested on the
same data bases. In fact, the multi-stream transformer was trained and tested only
on IBM MarketScan data. Note, the test set was still randomly selected from IBM
MarketScan and was unseen during the training process for all models. However,
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testing the proposed models on data sets other than IBM MarketScan is needed to
further test the generalizability of the models.

Copyright© Sajjad Fouladvand, 2021.
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